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ABSTRACT  
Background: Henoch Schönlein Nephritis (HSN) is a common childhood vasculitis that generally 
has a self-limiting course but the long-term outcome varies with the clinical picture at onset. 
Morbidity is high among the most severe cases, and therefore there is a need for intervention. 
Immunoglobulin A nephropathy (IgAN) is the most frequent glomerulonephritis in the world, and 
the risk of disease progression to chronic renal disease (CKD) is as high in paediatric population as 
among adults. There is no consensus regarding treatment strategies in the two diseases. Aim: To 
identify patients at risk and to identify predictors of a poor outcome in HSN and IgAN patients and 
to study the results of treated patients with severe forms of HSN and IgAN. Results: In study I 73 
patients with HSN, investigated within 5 years from onset, we observed that GFR at the first 
investigation was lowest among patients with nephrotic syndrome or with a nephritic-nephrotic 
picture at onset. The clinical picture at onset was related to the histology findings. Advanced biopsy 
findings were found in 60% of patients with nephrotic syndrome and in 70% of patients with a 
nephritic-nephrotic picture at onset. Among patients with non- nephrotic proteinuria, generally 
considered to be a benign group, 69% showed advanced biopsy findings, despite the fact that their 
GFR showed only a moderate reduction at onset. In study II the results of treatment of the most 
severe cases of HSN (n=24) and IgAN (n=19) were presented. All patients were treated with 
ACEi/ARB. In group A (n=18) Methylprednisolone/oral prednisolone was combined with 
Cyclophosphamide given as 3-6 monthly pulses. In group B (n=25) 15 patients received 
corticosteroids and 10 only ACEi/ARB. In group A proteinuria was reduced after 
Methylprednisolone and further declined after Cyclophophamide treatment. GFR improved during 
follow-up in group A. In group B the proteinuria decreased during follow-up and the GFR remained 
unchanged. There was a greater fall in the protein reduction in the group treated with corticosteroids 
and ACEi/ARB than in the group treated without corticosteroids. The results presented in study III 
identified the predictors of a poor outcome in 78 HSN patients followed mean 5 years. 26% 
progressed to a poor outcome (active renal disease or CKD stage 4-5/ESRD). Both severe clinical 
features at onset and advanced biopsy findings were related to a poor outcome. Proteinuria at one 
year follow-up was assessed as a strong individual predictor. The combination of proteinuria at one 
year and the histology grading showed highest discriminative ability. The results in study IV 
validated the new Oxford classification and assessed the predictability of the of the histology 
findings identified in the Oxford MEST score: mesangial (M) and endocapillary (E) hypercellularity, 
segmental glomerulosclerosis (S) and tubular atrophy/interstitial fibrosis (T). Ninety-nine children 
were followed > 5 years. Eighteen per cent progressed to a poor outcome. Ninety biopsies were 
reviewed according to the MEST score: M, E and T were each associated with a poor outcome but S 
did not reach significance. Instead, presence of crescents and of global sclerosis was predictive of 
poor outcome in our cohort. Conclusion: Morbidity is high among severe cases of HSN and IgAN. 
Identification of predictors of a poor prognosis will improve medical intervention and reduce the risk 
of deterioration of the diseases. 
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INTRODUCTION 
1.1 Brief historical remarks 
Henoch Schönlein Purpura (HSP) is a leukocytoclastic vasculitis with a multi-organ 
engagement, primarily affecting the skin but also the joints, the intestine and the kidneys. 
The first report of the disease was published 1802 by Heberden [1, 2] and in 1837 
Schönlein found the association between rash (purpura) and joint pain. Henoch added the 
gastrointestinal symptoms in 1874 and 25 years later renal engagement was explored. From 
the 1920s it was known that the morbidity of the HSP syndrome, at the time called 
Anaphylactoid purpura, was due to the severity of glomerulonephritis. The 
immunofluorescence technique developed during the late 1960s and in 1968 Berger and 
Hinglais reported a form of glomerulonephritis, in which the renal damage was due to 
identified mesangial accumulation of IgA deposits. The disease was named Berger´s 
disease [3]. In the same decade IgA deposits were also identified in renal biopsies from 
patients with Henoch Schönlein nephritis (HSN) [4].  
 
1.2 Epidemiology 
Henoch Schönlein purpura (HSP) is the most common form of vasculitis in childhood with 
an annual incidence of 10-20/100 000 children [5-7]. The estimated annual incidence varies 
among different ethnic groups in paediatric populations and is higher among Asian children 
than among Caucasian children [7]. The age distribution at onset range from 2 to 18 years 
and the peak incidence occurs at 4-6 years. It is considered to be a self- limiting disease in a 
majority of the cases. The long-term prognosis is related to the renal engagement, Henoch 
Schönlein Nephritis, which occurs in 35% (40-60%) of the  HSP patients [2, 3, 8-10] and 
accounts for 10-15% of the paediatric glomerulonephritis [11]. In biopsy data from our 
center during the years 1994-2000 HSN accounted for 8% of all biopsies. Children who are 
older at onset tend to have a higher risk of renal involvement [2, 8] and of advanced renal 
disease [12].  
Immunoglobulin A nephropathy (IgAN) is the most common type of glomerulonephritis in 
the world with frequency that varies geographically. As in HSN, there is a higher frequency 
in Asian than in Caucasian populations. The annual incidence in adult population in France 
is 25-30/million, in Japan 45/million and in USA 12/million [13]. The incidence figures can 
be explained by the different regional sampling procedures, such as indications for a renal 
biopsy and there can also be genetic explanations. The male/female ratio indicates that 
males are more likely to be affected by the disease, generally in the second and third decade 
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of life [13, 14], but the onset of the disease can occur in children as young as 2-3 years of 
age.  
 
1.3 Pathogenesis 
1.3.1 Trigger factors 
 HSN and IgAN are considered to be related diseases with a common pathogenetic 
pathway. The diseases are usually proceeded by a bacterial or viral infection [2, 3, 15]. 
Allergic manifestations caused by drugs and insects bites have also been reported as 
stimulus for HSP induction, but no causal relationship has been determined [16, 17]. 
Regardless of which antigen triggers, an immunologic process starts and forms immune 
complexes which circulate in the blood and then form depositions primarily in the 
mesangial matrix (Figure 1). With increasing mesangial proliferation and mesangial matrix 
expansion, the architecture of the glomerular capillary wall is gradually destroyed. If the 
renal damage proceeds, the glomerular filtration is reduced temporarily or permanently. 
 
1.3.2 Impaired IgA synthesis 
Most of the systemic IgA is produced in the bone marrow, lymph nodes and spleen and 
appears in monomeric form. The polymeric IgA is produced mainly by lymphocytes and 
plasma cells in the gastrointestinal and respiratory tracts [18]. Increased synthesis and 
release of the polymeric IgA1 (pIgA1) into the circulation is one of the factors involved in 
the pathogenesis of the diseases [19].Various mechanisms have been described and several 
aspects of the dysregulated IgA immune system have been discussed (Figure 2); Increased 
production, defective synthesis, decreased clearance of IgA1 and enhanced mesangial 
binding of IgA1 complex [20]. At present time the attention has focused on the defective 
galactosylation of the molecule [21] and poorly galactosylated IgA1 has been identified in 
the mesangium and sera from most IgAN patients [22]. 
a 
Figure 1. Normal glomerulus 
a. afferent arterioli,  b. efferent arterioli,  
c. capillary loops, d. Bowman´s capsule, 
e. mesangium 
  
 
b 
 c 
 d 
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The heavy chains of IgA1 with its hinge region contains up to six oligosaccharide chains 
composed by N-acetylgalactosamine (GalNAc) and attached residues [21, 23] (Figure 3).  
In patients with IgAN a galactose deficient form of IgA1 (Gal-deficient IgA1) is identified 
and appears to have a key role in the pathogenetic process [20, 21, 24]. Recent 
investigation suggest that HSN share this pathway [25, 26]. Increased levels of Gal-
deficient IgA1 in plasma has also been observed in patients with HSP who develop 
glomerulonephritis, but not in those without glomerulonephritis [21, 23, 25, 27].  
 
Figure 3. IgA1 and its hinge region with amino acid sequences.  
The lower structure shows normal galactosylation in healthy individuals and the upper structure the 
galactose deficient form found at elevated levels in patients with IgAN. Adapted from Beerman [28]. 
 
Donadio et al NEJM (2002) 347:738 
Figure 2.  
Potential mechanisms 
underlying glomerular 
deposition of IgA and 
progression of renal disease in 
IgA nephropathy.  
Adapted from Donadio et al [84]. 
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1.3.3 Mesangial deposition of IgA1 
The serum IgA molecule has a half-life of 4-5 days, before it binds to the receptor in the 
hepatocyte where it is catabolized and excreted. In IgAN the increased production and the 
decreased clearance leads to a longer lifespan of the Gal-deficient IgA1 [21]. The 
molecules are recognized by specific antibodies and form immunocomplexes which, due to 
their size, are less effectively taken up by receptors in the liver. Instead they pass from the 
blood to the mesangium through the endothelial fenestrae in the glomerular capillary wall, 
which permits the entry of large molecules [21]. The Gal-deficient IgA1 immunocomplexes 
have a high affinity to mesangial cells and the binding is facilitated by factors promoting 
mesangial trapping and mesangial proliferation [20, 21, 26, 29]. Of the complement 
components primarily C3 (60-100%) are co-deposited together with IgA1 and in some 
cases also with IgM (9-66%) and IgG (15-87%). The normal serum complement levels are 
consistent with an activity of the alternative or lectin pathway in the diseases, whereas 
complement components of the classical pathway such as C1q are not verified [18, 19, 30-
33]. Mesangial deposition of the immunocomplexes can induce complement activation 
which can influence the extent of the glomerular injury [3]. The complement deposits can 
be observed many years after the primary onset of disease [34, 35]. 
 
1.4 Grading of the glomerular damage 
1.4.1 Grading of glomerular damage in HSN  
The defining pathology in HSN and IgAN is the deposition of IgA1 in the mesangium and 
histological findings of mesangial proliferative glomerulonephritis. 
  
International Study of Kidney Disease in Children´s classification of Henoch Schönlein 
Nephritis 
grade  
 
I minimal glomerular alteration 
II mesangial proliferation  
IIIa  focal proliferation with < 50% crescents/ segmental lesions 
IIIb diffuse proliferation with < 50% crescents/ segmental lesions  
IVa focal proliferation with 50-75% crescents/ segmental lesions 
IVb diffuse proliferation with 50-75% crescents/segmental lesions 
Va focal proliferation with > 75% crescents/ segmental lesions 
Vb diffuse proliferation with > 75% crescents/segmental lesions 
VI membranoproliferative picture 
 
Table 1. The International Study of Kidney Disease in Children´s 
classification of Henoch Schönlein Nephritis [17, 36]  
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The histology pattern in HSN is graded according to the classification by the International 
Society of Kidney Disease in Children (ISKDC) in which the severity of renal damage is 
assessed and divided into six grades (Table 1). Grade I shows minimal glomerular changes. 
Grade II shows mesangial proliferation (Figure 4a) with or without endocapillary 
hypercellularity or mesangial matrix expansion. The amount of mesangial proliferation 
varies and can either be located diffusely or focally/segmentally. Severe mesangial 
proliferation is often accompanied with leucocyte infiltration and fibrin deposition in the  
 
 
 
glomeruli can also be found [37]. Grades I-II are defined as mild histology findings 
whereas presence of cellular/ fibrocellular crescents (Figure 4b) or fibrous crescents and/or 
segmental or global glomerulosclerosis as seen in grade III-V, are defined as advanced 
renal injury. In grade VI the glomeruli show a membranoproliferative picture, which is 
uncommon, and the high numerical grade gives a misleading impression of its severity, 
which is mainly determined by the frequency crescents. The formation of crescents is 
caused by proliferation of the epithelial cells of Bowman´s capsule, and may vary in size 
from small segmental/cellular to large global circumferential with fibrin deposits. 
Cellular/fibrocellular crescents are considered as markers of disease activity whereas 
fibrous crescents are signs of permanent injury, as well as segmental and global 
glomerulosclerosis [17, 38]. Repeated biopsies can show a spontaneous reduction of the 
number of glomeruli with fibrocellular or cellular crescent formations and also a complete 
reduction of mesangial proliferation [17, 33]. Apart from the glomerular findings the 
amount of tubular atrophy, interstitial inflammation and interstitial fibrosis also reflect the 
severity of renal damage [39]. Therefore, to obtain a differentiated pattern of the renal 
injury the tubulointerstitial findings can be evaluated separately. Andreoli and Bergstein 
[40] developed a scoring system for IgAN to differentiate acute from chronic histology 
Fig 4a. Mesangial proliferation. ISKDC II    Fig 4b. Cellular crescent. ISKDC ≥ III 
Figure 4a. Arrows show hypercellularity and mesangial matrix expansion. Figure 4b. Arrows show 
rupture of the basement membrane of Bowman´s capsule and infiltration of leukocytes and fibrin 
deposits  
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findings. Foster used introduced a scale for HSN biopsies that reflected the disease 
activity/chronicity highlighting the importance of tubulointerstitial findings in indicating 
the severity of the disease. [41]. 
 
1.4.2 Grading of glomerular damage in IgAN  
The histologic pattern in IgAN varies widely, from signs of mild injury to advanced renal 
damage. The classification systems for IgAN have been less straight forward than for HSN. 
Based on numerous reports on which lesions that best predict a poor outcome, consensus 
was not reached until recently, when the Oxford classification was published in 2009 [42, 
43], a result of international collaboration in the International IgA Nephropathy Network 
and the Renal Pathology Society. The classifications previously used (the Lee classification 
[44, 45] and the Haas classification [46]) are now gradually replaced by the Oxford 
classification, in which four lesions with the most prognostic importance are identified: 
Mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis 
and tubular atrophy/interstitial fibrosis. The results have been analysed using a systematic 
approach, in order to develop a reproducible classification with a scoring system (MEST 
score) which can improve individual patient prognostication (Table 2). The Oxford 
classification MEST score has also been applied in paediatric biopsies [47]. The validity of 
the scoring system to assess the severity of the renal lesion and its usefulness as a 
prospective tool has not been established previously in paediatric IgAN. 
Histology  finding  Definition Score 
Mesangial 
hypercellularity 
< 4 mesangial cells/mesangial area=0 
4-5 mesangial cells/mesangial area=1 
6-7 mesangial cells/mesangial area=2 
>8  mesangial cells/mesangial area=3 
M0≤ 0.5 
M1> 0.51 
Endocapillary 
hypercellularity 
Hypercellularity due to increased number of cells 
within the glomerular capillary causing narrowing of 
the capillary lumina 
E0= absent 
E1= present 
Segmental 
glomerulosclerosis 
Any amount of the tuft involved in the sclerosis but 
not involving the whole tuft, or presence of adhesions 
S0= absent 
S1= present 
Tubular 
atrophy/interstitial 
fibrosis 
% of cortical area affected by tubular atrophy or 
interstitial fibrosis, whichever is greater 
T0=0-25% 
T1=25-50% 
T2 >50% 
 
Table 2. Definitions of histology findings used in the Oxford Classification of 
IgA Nephropathy [42].  
1 The mean score for all glomeruli is calculated but if >50% of the glomeruli have > 3 cells in the mesangial area it is 
categorized as M1 
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1.4.3. Differences in renal pathology findings in HSN compared to IgAN  
Renal morphology findings in HSN are identical to those of IgAN although the frequency 
and distribution may differ. Cellular or fibrocellular crescents, deposits of fibrin in the 
glomeruli and endocapillary proliferative findings are often more found in severe in HSN 
than in severe IgAN [30]. Deposits of IgA along the capillary wall have been associated 
with more severe clinical manifestations and a poor outcome both in HSN and in IgAN. 
This finding is also more frequent in HSN than in IgAN [18, 48]. 
 
1.5 Clinical onset and course of the disease 
1.5.1 Clinical features at onset and relation to outcome in HSN  
HSN is in most cases a self-limited disorder, but there is a risk of permanent renal damage 
and deteriorating renal function [12, 49]. The long-term prognosis of HSN is related to the 
clinical features at onset and to the renal biopsy findings. Patients with mild symptoms i.e 
hematuria and/or mild proteinuria  at onset are generally considered to have a good 
prognosis, with a risk of long-term impairment of less than 2% [2, 6, 50-52]. The risk of a 
poor ourcome increases for patients with severe symptoms at onset (Table 3). Patients who 
presents a nephritic, nephrotic or a mixed nephritic-nephrotic picture, have an estimation of 
long-term impairment of 20% [1, 12, 33, 36 , 52-54]. However, the clinical course in 
children is more unpredictable than among adults [55] and the renal function can 
deteriorate many years after apparent remission [54].  
Study n 
HSP/HSN 
Poor 
outcome 3 
n (%)  
Follow-up 
years 
Mild1  
symptoms 
n (%)  
Severe2 
symptoms 
n (%)  
Steward et al [6] 270/55 1 (2) 8.3 0 1/18 (5)  
Saulsbury et al [2] 100/40 1 (2) - 0 1/9 (11) 
Goldstein et al [54] 78 22 (28) 23 5/39 (13) 17/39 (44) 
Schärer et al [56] 64 21 (33) 6.1 3/26  (8) 18/38 (47) 
Ronkainen et al 
[12] 
47/38   9 (23) 24 2/18 (11) 7/20 (35) 
 
Table 3.  
HSN patients with poor outcome related to severity of renal symptoms at 
onset in the five largest studies. 
1 = Hematuria ± proteinuria with Ualb/c < 200 mg/mmol, 2 = Nephritic or nephrotic or mixed clinical picture 
3 = Active renal disease (hypertension ± proteinuria ± decreased GFR) or renal failure/ERSD 
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1.5.2 Clinical features at onset and 10 year survival in IgAN patients  
The initial features at presentation in paediatric IgAN varies geographically. In Japanese 
series, in which patients at risk are identified by urinary screening, the clinical presentation 
at onset is most often microscopic hematuria (60%), whereas in studies from the United 
States and Europe, macroscopic hematuria is the most frequent initial finding (50-80%) 
[39, 57-59]. The onset is rarely acute nephritic or nephrotic syndrome (10%) [60]. In 
paediatric patients with isolated microscopic hematuria, the proteinuria often occurs after 
several years (mean 5 years) [39]. In several centers the indication for a renal biopsy is 
limited to patients with macroscopic hematuria or microscopic hematuria in combination 
with proteinuria. Therefore the disease can proceed undiagnosed for many years.  
Compared to adults, children are less likely to have impaired GFR at time of biopsy, tend to 
have lower blood pressure at time of biopsy and are more likely to have had recurrences of 
macroscopic hematuria [39]. The most common clinical course is a slow progression to 
renal insufficiency, but the rate of progression is variable and the outcome is difficult to 
predict [18]. Few cases of full clinical recovery exists [39, 59, 61, 62], in some cases with a 
disappearance or diminution of mesangial IgA deposits [48]. Previously IgAN was 
considered to be less progressive in young ages. However, according to several reports the 
20-year renal survival analysis showed that children have as progressive disease as adults 
[14, 59, 62, 63]. The actuarial 10-year renal survival in adult patients with childhood onset, 
shows apparent geographic variations according to the most accurate studies during the 
years 1984-2000; Europe 83-94%, Asia 74-91% and North America 57-78% [14]. More 
recent studies show an improved expected 10-year survival in the majority of the cases 
(Table 4). Studies have shown that IgAN patients diagnosed in childhood have better long 
term survival than those diagnosed as adults [59, 64, 65]. The differences might be due to 
improved follow-up routines and also to the fact that adult biopsies reveal more advanced 
chronic histology lesions, reducing the opportunities for medical intervention [64]. 
Study Patients 
n 
at 10 years (%) at 20 years 
(%) 
Ethnicity 
Wyatt 1995[63] 103 87 73 Caucasian/AfroAm 
Nozawa 2005 [66] 181 92 89 Japanese 
Ronkainen 2006 [59] 55 93 87 Finnish 
Hastings 2007 [67] 67 91 80 Caucasian 
Haas 2008 [64] 99 87 - Caucasian 
 
Table 4.  
Predicted renal survival of IgAN with childhood onset adapted after Coppo [39] 
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AIM 
The aim of the study was to identify risk factors of a poor prognosis in HSN and IgAN 
 
  To assess how the clinical picture at onset was related to renal function and to 
morphology in HSN (study I) 
  To study clinical and functional results of treated patients severe HSN and IgAN 
(study II)  
 To assess predictors of a poor prognosis in HSN (study III) and IgAN (study IV) 
 To validate the prognostic significance of the new Oxford classification of IgAN in 
pediatric patients (study IV) 
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METHODS AND MATERIAL 
3.1 Renal function 
3.1.1. Clearance investigations and definition of CKD  
The clearance of one substance from a compartment is defined as the ratio between the 
elimination rate of the substance from that compartment, and the concentration of the 
substance in the same compartment. The calculated value of clearance is expressed as 
ml/min and is corrected for a standard body surface area (BSA) of 1.73 m2.  
The measurement of glomerular filtration rate (GFR) requires a biologically inert 
substance, which passes freely through the glomerulus and is excreted without being 
reabsorbed, metabolized or secreted in the tubuli. Inulin, a polymer of fructose, has been 
considered the ideal substance for GFR measurement. This marker is given intravenously 
either as a constant infusion or as a bolus injection (single injection). Renal clearance (C) is 
calculated using the formula C = U x V/P in which U= urinary concentration of the 
substance (mg/ml), V= diuresis (ml/min) and P= plasma concentration of the substance 
(mg/ml). However, this method has its disadvantages. It is time consuming, and the bladder 
has to be emptied completely to avoid measure defaults. Additionally, the increased costs 
for Inulin (Inutest), has created a demand for an alternative filtration marker. Therefore the 
single injection technique with Iohexol, a low-osmolar contrast medium, has gradually 
replaced Inulin over the last five years. The method is cheaper and does not require urinary 
sampling. Comparisons have shown a good agreement between the renal clearance with 
Inulin and the plasma clearance with Iohexol [68]. 
The effective renal plasma flow (ERPF) is determined with a marker which is totally 
cleared from the plasma by glomerular filtration and tubular secretion. Para-aminohippuric 
acid (PAH) is a suitable substance for these estimations. The filtration fraction (FF) is 
calculated as a ratio between GFR and ERPF.  
All clearance values in studies I-IV are expressed as ml/min/1.73m2 adjusted to BSA which 
is calculated from the Haycock formula [69].  
In the year 2002 the National Kidney Foundation´s Kidney Disease Outcomes Quality 
Initiative (NFK/K/DOQI) set guidelines to classify levels (stages 1-5) of chronic kidney 
disease (CKD) in adults according to the level of GFR [70]. The stages and the associated 
recommendations have also been assessed for children > 2 years of age and for adolescents 
[71]. In this classification CKD is defined as 1) presence of kidney damage defined by 
structural or functional abnormalities with or without reduction of GFR or 2) GFR ≤ 60 
ml/min/1.73m2 for three months or more irrespectively of the diagnosis. Kidney failure is 
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defined as GFR ≤ 15 ml/min/1.73m2 or end stage renal disease (ESRD) requiring dialysis 
or transplantation.  
 
3.1.2 Clearance of Inulin and of PAH during water diuresis 
A prime dose (64 mg/kg) of Inulin (Inutest, 25% Fresenius Kabi Austria GmbH, Graz, 
Austria) is injected intravenously and a prime dose (9 mg/kg) of PAH (PAH, 20%, MSD, 
West Point, USA) followed by a continuous infusion of Inulin 1-2 mg/kg/min and PAH 
0.15-0.3 mg/kg/min. After an equilibration period of 60 minutes, the infusion is continued 
for another two hours. A total of four urinary collections are obtained with an interval of 30 
minutes. In the middle of each collection period a blood sample is drawn. Water diuresis is 
obtained by oral water intake of 20 ml/kg during the first hour, and then 5 ml/kg every 30 
minute up to a maximum of 1200 ml and 300 ml respectively and no catheter is used. A 
mean value of the four collected periods is calculated [72]. Inulin concentrations in blood 
and urine is determined by an enzymatic technique [73] and PAH by photometric analysis.  
 
3.1.2 Clearance of Iohexol  
Iohexol (Omnipaque 300 mg/ml, GE Healthcare, Stockholm, Sweden) 5 ml is injected 
intravenously and blood samples are drawn from the contra-lateral arm after 180, 200, 220 
and 240 minutes if the GFR is predicted to be > 50 ml/min/1.73m2. The investigation 
continued and a blood sample is drawn after 420 minutes if predicted GFR is 20-50 and 
after 1440 minutes if predicted GFR is < 20 ml/min/1.73m2. Clearance is calculated from 
the slope of the plasma concentrations using a pharmacokinetic one-compartment model 
with the modification of Bröckner Mortensson [74, 75]. Plasma concentration of Iohexol is 
determined by high-performance liquid chromatography [76]. 
 
3.2 Proteinuria 
3.2.1 Filtration barrier 
The blood is filtered through the glomerulus to the urinary space through several layers; the 
endothelial cell surface layer (ESL), the endothelial cell coat layer of fenestrated cells, the 
basement membrane (GBM) and a layer of glomerular epithelial cells (podocytes) which 
are separated by narrow gaps (slit membranes) [77]. The basement membrane consists 
mainly of collagen type IV with high density, an effective filtration barrier which works 
primarily selectively as it forms a network restraining larger molecules  
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(> 45 Å in diameter) while the smaller ones (< 20 Å) pass [78]. The barrier also constitutes 
a charge selectivity that repels the negative albumin molecules. The podocyte and the slit 
pores with their specialized differentiated functions, play a pivotal role in the intact barrier. 
The size and charge selectivity of the glomerular barrier has been questioned during the last 
decade, but the classical view still holds [79, 80]. 
 
3.2.2 Proteinuria detection levels 
Quantification of proteinuria has traditionally demanded a timed urinary collection, usually 
performed over 24-hours. The timing and volume problems in the young children, who 
have not achieved continence, and the need to correct the protein excretion rate for body 
surface area, make this method cumbersome. The Clinical Practice Guidelines for Chronic 
Renal Disease in Children and Adolescents published in the NKF-K/DOQI recommends 
untimed (spot) urinary samples, in which the ratio of the urine albumin/urine creatinine 
(Ualb/c, mg/mmol) can be calculated to detect and monitor proteinuria in children [71]. 
Studies have shown a high correlation between Ualb/c ratio to 24-hour collected protein 
excretion [81, 82], and the method requires no correlation to BSA. The method provides the 
most accurate measurement of albumin clearance and provides a good marker of 
glomerular permeability [70]. 
Levels of 
albuminuria 
Protein excretion  Dipstick Ualb/c              24-hour  collection Normo  insignificant 0  < 4mg/m2/h  Mirco <0.2 g/L trace 2-25 30-300 mg/d  <0.3 g/L +1   Mild <1 g/L +2 >25-200  Moderate   >200-400  
Nephrotic 3 g/L +3 >400 >40mg/m2/h 
(>1g/1.73m2/d)  
 >20 g/L +4   
 
Table 5. Levels of proteinuria and their quantification measurement methods 
 
 
Figure 5. The glomerular 
filtration barrier 
Adapted after Haraldsson et al 
[79] 
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3.3 Renal biopsy  
3.3.1 Indication of investigation with a renal biopsy 
In HSN the diagnosis is based on the clinical picture and a renal biopsy is not mandatory 
for diagnostic purposes, in the majority of the cases. However, as the long-term prognosis 
is related to the severity of renal disease at onset, it is a common strategy to perform an 
early renal biopsy if the clinical presentation shows an acute nephritic or nephritic 
syndrome or a mixed clinical picture [15, 51, 53, 83]. If the duration of a non-nephrotic 
proteinuria persists more than a few months from onset, or if the GFR declines, we 
recommend a biopsy, which to our knowledge is less likely to be a common strategy. 
The investigations recommended for patients with suspected IgAN differs geographically. 
The indication for a renal biopsy in our center is persistent asymptomatic isolated 
hematuria for minimum two years. In other centers there is a more restricted policy with a 
biopsy reserved for patients with macroscopic hematuria or persistent microscopic 
hematuria with additional proteinuria > 1g/d or impaired renal function [24, 63, 84]. A re-
biopsy of IgAN patients is undertaken in our center, if there is a deterioration of renal 
function and/or an increase in albuminuria despite RAAS blockade. 
 
3.3.2. Ultrasound guidance 
The renal biopsies are performed percutaneously with ultrasound guidance, using an 
automatic device with a 16-gauge needle (Bard Magnum Biopsy Instrument and Core 
Tissue Biopsy Needle, Urological, Covington, CA, USA). The method has been validated 
in a previous study by our group [85].  
 
3.3.3 Preparation and examination of the biopsy 
The biopsies are fixed in 4% paraformaldehyde in phosphate buffer and analysed based on 
three micron PAS-stained sections. The preparations of tissue for immunofluorescence are 
frozen in liquid nitrogen, cut 5 μm thick and incubated with standard anti-antibodies. All 
biopsies are examined with light microscopy and immunofluorescence investigation and if 
the diagnostic criteria were not fulfilled, also with electron microscopy. 
The biopsies in all four studies were examined by the same pathologist (MPS), who was 
blinded to patient outcome at the time of his investigation. The ISKDC classification was 
used in HSN biopsies in study I-III and the Oxford classification for the cases in study IV. 
In study II the ISKDC classification was used for both HSN and IgAN cases. In the articles 
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I-III we used the ISKDC classification without the subgroups a) and b) and thus we did not 
differentiate focal proliferation from diffuse (see Table 1). In study I-III amount of the 
mesangial proliferation, mesangial matrix expansion, interstitial inflammation and 
tubulointerstital findings were graded in a four -graded scale (0-3). In study II the biopsies 
are additionally classified according to signs of activity/chronicity [40, 41]. Our modified 
scoring system was based on mesangial matrix expansion/mesangial proliferation (0-3) and 
per cent of glomeruli with cellular or fibrocellular crescents (0-3) as indicators of activity. 
Indicators of chronicity were per cent of glomeruli with global or segmental 
glomerulosclerosis (0-2) and the amount of interstitial fibrosis (0-3). The scoring of 
interstitial fibrosis was doubled due to its impact on progressive histological damage [46, 
48, 86-88].  
 
3.4 Blood pressure 
Office blood pressure was measured with an oscillometric device (Dynamap Newport, 
USA). The blood pressure was measured from the right arm, in a sitting position after 5 
minutes of rest. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
measured and mean arterial blood pressure was calculated as DBP + (SBP-DBP/3). 
Hypertension was defined according to recommendations from the Working Group of 
National High Blood Pressure Educational Program and adjusted for age, sex and height 
[89].  
 
3.5 Patients and controls 
The cohorts in studies I-IV mainly consisted of referral patients with a high proportion of 
cases with severe disease. This fact is expressed in Table 6 in which shows a high age at 
onset, a high proportion of biopsied patients and a high proportion of treated patients. The 
age matched control group consisted of healthy patients who had undergone a renal 
function investigation due to a suspicion of a renal disease, which could not be verified. 
The number of patient included in each study and their overlapping is shown in Figure 6. 
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Article  I  II III IV 
                      all/ study group 
 
N  73 43  103/78 99 
  
Age at onset years    8 12        9/9  12  
Male (%)  44 58    49/47  59 
Follow up time years  <5 3.1  4.6/5.2  13 
HSN (%)  100   56       100    0 
IgA (%)     0    44          0 100 
Biopsied patients (%)  54 100    68/75   90 
Treated patients (%)    0 100        /38   35 
ESRD patients (%)    0   14          /4   13 
Controls (n)    49   50         50   59 
    
 
Table 6. 
Descriptive data of patients and number of controls included in studies I-IV  
 
 
 
 
 
Figure 6.  
Number of patients in studies I-IV and their overlapping  
The figures above the lines refer to the number of patients included in both studies. 
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3.6 Statistical methods 
3.6.1 Descriptive statistics 
The data was presented using mean and standard deviation, when normally distributed. 
When data was not normally distributed it is presented with median and range (minimum-
maximum).  
 
3.6.2 Overview of statistical methods 
All calculations were done using Statistica v 7.0, Tulsa USA. Student´s t test was used for 
normally distributed data and the Mann-Whitney U-test for data with a skewed distribution. 
The chi-square test was used to test for differences between proportions, i.e. categorical 
variables. For comparisons of repeated measurements in skewed data Wilcoxon´s matched 
pairs test was used. To compare mean in variables with more than two groups, one-way 
analysis of variance (ANOVA) was used, followed by the post-hoc test of Tukey-Kramer 
for pairwise comparison. Linear regression with the Pearson´s correlation was used when 
comparing continuous variables and the Spearman correlation coefficient when ordered 
categorical data were compared. To estimate the discriminative efficacy of predictors of 
poor outcome logistic regression was used with univariate and multivariate analyses. 
Renal survival data were explored using the Kaplan-Meier curve with the corresponding 
log rank calculations between groups of clinical and pathologic variables, with respect to 
time-to-poor outcome. Cox proportional hazard regression (HR) was used to estimate the 
hazard ratio between groups within each factor for the time-to-poor outcome. 
Estimates were presented with their corresponding 95% confidence intervals (CIs).  
Multiple hazard regression was used to estimate a model including a combination of the 
independent factors of interest, and was also used to explore which factors were the overall 
most important discriminators for time-to-poor outcome. All tests were two-sided and a P-
value < 0.05 was considered as statistically significant. 
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Study                       I   II       III                 IV 
Method     
     
ANOVA x    
Student´s paired 
t-test  x x x 
Mann-Whitney U- 
test  x x x 
Chi square test  x x x 
Wilcoxon´s 
matched pairs 
test 
 x   
Linear regression   x x 
Spearman rank 
correlation 
coefficient 
x  x x 
Logistic 
regression (Odds 
ratio) 
  x  
Cox proportional 
hazard regression    x 
Kaplan- Meier 
survival analysis    x 
 
Table 7.  
Statistical methods used in studies I-IV  
 
 
ETHICAL APPROVALS 
The studies in article I-III were approved by the Ethics committee at the Karolinska 
University Hospital, Huddinge (no 262/97) and the study in article IV was approved by the 
Regional Ethical Review Board (no 2010/290-31/3).  
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RESULTS AND DISCUSSION         
5.1 Clinical features and histology findings in HSN patients  
Results of study I  
The main factors in defining risk patients in HSN are highlighted in the study of 73 HSN 
patients biopsied within five years from onset. The relation between clinical and functional 
results at onset was compared to histology findings. The clinical features at onset/ biopsy in 
studies I-III are shown in Table 8. 
Study  I 
n=73 
    II 
n=43 
 III 
 n=78 
 
HEM micro/ 
macro 
hematuria 
 
12      0  12  
PROT  
 
persistent 
mild 
proteinuria1 
27  14  34  
AN  acute 
nephritic 
syndrome2 
17  8  10  
NS  
 
acute 
nephrotic 
syndrome3  
6 34 (47%) 12 29 (67%) 8 32 (41%) 
AN+NS mixed 
clinical 
picture  
11  9  14 
 
 
 
Table 8.  
Number of patients in relation to symptoms at onset/at biopsy in study I-III 
1 Urine albumin < 1g/L or Ualb/c< 200 mg/mmol ± hematuria,  
2 Ualb/c ≥200-400 mg/mmol, hematuria, decreased GFR ± hypertension [89] 
 3 Ualb >40 mg/h/ m2 BSA or Ualb/c >400 mg/mmol and serum albumin < 25g/L ± oedema 
 
In study I the GFR at the first investigation (GFR:first) was lowest among patients with 
nephrotic syndrome or with a nephritic-nephrotic picture at onset. It was significantly lower 
compared to patients with only hematuria at onset and to controls. Among patients with 
non- nephrotic proteinuria, GFR:first was only slightly reduced compared to controls. 
There was an inverse correlation between GFR:first and the amount of proteinuria. 
GFR:first was significantly lower in patients with proteinuria in the nephrotic range 
compared with normo/micro-albuminuric patients. Grade III was the most frequent ISKDC 
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grade and 68 % of the biopsies showed ISKDC ≥ III. The frequency of the biopsy findings 
according to their classification in studies I-IV is shown in Table 9.  
                   ISKDC histology 
               grading of HSN 
Oxford classification 
MEST score of IgAN 
 
Study 
 
n Mild 
I-II 
n (%) 
Advanced 
III-V 
n (%) 
No MEST 
C0/GGS0 
n (%) 
Any MEST 
C1/GGS1 
n (%) 
 
I 40 13 (32) 27 (68)   
II 43 8(19) 35 (81)   
III 59 21 (36) 38 (64)   
IV 90   50 (55) 40 (45) 
 
Table 9.  
Frequency of biopsy findings according to the ISKDC or to the Oxford 
classification in studies I-IV  
ISKDC I-V: Definitions as in Table 1 and in the text section 1.4.1.  
Oxford classification: Definitions as in Table 2 and in the text section 1.4.2 
C0=No cellular/fibrocellular crescents, C1=presence of cellular/fibrocellular crescents  
GGS0= No global glomerulosclerosis, GGS1= presence of global glomerulosclerosis  
 
 In study I the clinical picture at onset was related to the histology findings. Advanced biopsy 
findings were frequent among patients with nephritic syndrome or a nephritic-nephritic onset 
(60% and 70% respectively). Unexpectedly, in patients with mild to moderate proteinuria, a 
group that is generally considered to be benign, the frequency advanced biopsy findings was 
equally high (69%) despite the fact that their GFR showed only a moderate reduction at 
onset. Patients with cellular or fibrocellular crescents had lower GFR and more proteinuria 
than patients without this lesion. GFR deteriorated and proteinuria increased with more 
advanced histology findings.  
The clinic-pathological correlations have been observed in a number of studies [1, 33, 36, 
55, 90-92] in which severe symptoms are well correlated with the severity of the histology 
findings, thereby presenting the prognostic dependence thereof. More recent studies 
specifically highlight the risk of a poor outcome in patients with nephritic syndrome or with 
nephritic-nephrotic onset [12, 51, 56, 93]. Our results show that not only nephrotic 
proteinuria, but also persistent non-nephrotic proteinuria correlate with advanced biopsy 
findings and impaired GFR at time of biopsy. These patients therefore need close monitoring 
and follow-up. 
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5.2 Effect of treatment in patients with severe HSN and IgAN  
Results of study II  
The results of two treatment strategies were retrospectively studied in 43 patients (24 HSN, 
19 IgAN) with severe forms of disease. All patients received ACEi and/or ARB. Eighteen 
patients received treatment A: Methylprednisolone pulses followed by oral prednisolone 
(n=12), starting dose 1 mg/kg daily and then tapered during 3-6 months and additionally 
Cyclophosphamide pulses given 3-6 times monthly. Twenty-five patients received treatment 
B: ACEi and/or ARB with (n=15) or without (n=10) corticosteroids given as in treatment A. 
In group A all except one patient had severe clinical features at biopsy and advanced biopsy 
findings. The corresponding figures for patients in group B were 48% and 72% and 
respectively.  
Proteinuria was reduced in both groups after treatment with Methylprednisolone. In group 
A proteinuria was further reduced after treatment with Cyclophosphamide. The effect was 
sustained up to10 years with a median of 3 years. In group B, the 15 patients treated with 
corticosteroids in combination with ACEi/ARB had a greater fall in proteinuria, than in the 
group with no corticosteroid treatment. GFR in group A increased after treatment and 
remained unchanged in group B.  In the nine re-biopsied patients, the activity index, based 
on the percentage of cellular/fibrocellular crescents and the amount of mesangial 
proliferation, decreased. The chronicity index, based on percentage of segmental and global 
glomerulosclerosis and the amount of interstitial fibrosis, increased. The frequencies of 
patients in the different outcome groups in studies II-IV are shown in Table 10.  
Outcome n A B C D 
Study  n (%) n (%) n (%) n (%) 
 
II 
     
all 43 18 (42) 8 (18) 11 (26) 6 (14) 
HSN 24 12 (50) 3 (12) 7 (30) 2 (8) 
IgAN 19 6 (32) 5 (26) 4 (21) 4 (21) 
      
III 78 48 (61) 10 (13) 17 (22) 3 (4) 
      
  good outcome  poor outcome  
IV 99 81 (82)   18 (18)  
      
 
Table 10. Number of patients in the different outcome groups in studies II-IV 
A: no or minor urinary abnormalities, B: persistent mild proteinuria and a normal GFR, C: active renal 
disease Ualb/c ≥ 200 mg/mmol and/or hypertension and/or GFR 41-93 ml/min/1.73m2 (study II) GFR 
31-93 ml/min/1.73m2 (study III), D: GFR ≤ 40 ml/min/1.73 m2 or ESRD (study II); GFR ≤ 30 
ml/min/1.73m2 or ESRD (study III). Definition of outcome in study IV: Poor outcome if GFR:last is 
reduced >50% from GFR at biopsy or if deterioration to ESRD (see section 5.4)  
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In study II 40% of the patients the disease deteriorated to a poor outcome, found in 9/18 
(50%) of the patients in group A and 8/25 (33%) in group B. Since patients in group A in a 
higher proportion had a more advanced disease than patients in group B no conclusions on 
treatment efficacy can be made. There were no significant differences in the results of any 
clinical variable between HSN and IgAN patients at any point in time during follow-up, 
and no significant differences in outcome between HSN and IgAN. 
The recommendation regarding how to treat severe cases has changed over time. 
Immunosuppression was not commonly used before the years 1998-2000, and the use of 
RAAS blockade has also increased over the years in both diseases. The improved regimen 
is shown to ameliorate the outcome in study II. Patients with onset of the disease before 
1998 more frequently progressed to a poor outcome, than patients with a later onset 
(P<0.01). On the other hand several factors make the nephrologist reluctant to use 
aggressive immunosuppression. Aware of the fact that spontaneous resolution in HSN has 
been described [6, 36] and the concern of the significant side effects of Methylprednisolone 
and of Cyclophosphamide [94], the question of treatment requires careful consideration. 
Therefore an overview of the most important studies in the field is presented below. 
 
5.3 Overview of treatment strategies  Treatment in HSN patients  
Treatment aims at preventing long-term renal morbidity in high-risk patients, but there is 
no consensus on treatment recommendations. In studies of patients with severe HSN there 
have been several observational studies of various regimens, but there are few randomized 
controlled trials offering firm evidence of the best therapeutic practice. Due to the scarcity 
of the severe cases, the majority of the observational studies published include few patients 
(in 13/18 studies ≤ 20 patients are included) [95]. The studies show effectiveness of several 
immuosuppressive treatment strategies: Methylprednisolone followed by oral 
corticosteroids [93], corticosteroids in combination with Azathioprine [41, 96] , 
Cyclophophamide [51, 97-102], with or without anticoagulants [103], with or without 
plasmapheresis [56, 104, 105], Cyclosporine A [106-108], Mycophenolate mofetil [35, 
109] or Immunoglobulin therapy [110]. In contrast, in one of the few randomized 
controlled study in HSN, the authors found no evidence favouring Cyclophoshamide versus 
supportive therapy [98]. There is still insufficient data to present evidence-based 
recommendations for the use of pulse or oral corticosteroids, either alone or in combination 
with Azatioprine or Cyclophosphamide. The use of ACEi and ARB to HSN patients with 
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mild to moderate proteinuria is frequently used based on the satisfactory results obtained 
with this regimen in IgAN (see below). 
  Treatment in IgAN patients 
Several treatment approaches have been explored in IgAN [111], but no specific curative 
treatment has been established. In paediatric studies the long time period from apparent 
clinical onset to progression of ESRD creates a need for surrogate markers of a poor 
prognosis to enable evaluation of interventions [112]. 
In adult IgAN patients treatment with ACEi [113], with or without the combination of ARB 
[114, 115] or ARB alone [116] in both normotensive and hypertensive patients has been 
shown to be effective in preserving GFR and reducing proteinuria. A superior effect of a 
combination therapy of ACEi plus ARB has been clearly demonstrated in the 
COOPERATE trial [117] of adult non-diabetic patients, of which 50% had IgAN. The 
study establishes that ACEi and ARBs preserve renal function equally and that the 
combination of the two preserves the renal function more effectively than either therapy 
alone. 
The most convincing study of the effect of ACEi in IgA children and adults (9-35 years 
old) with moderate proteinuria is an Italian randomized controlled study from 2007 [118] 
(Table 11). Sixty-six patients (32 children) with proteinuria > 1g < 3g/day/BSA and normal 
or moderately reduced renal function (GFR > 50 ml/min/1.73m2 were included and 
randomized to Benazepril (ACEi) or placebo. The end point was a 30% decrease in 
creatinine clearance or worsening of proteinuria exceeding nephrotic range. The results 
demonstrated a beneficial effect of ACEi. Patients in the treated group had a significant 
reduction of proteinuria and less deterioration of GFR compared to the placebo group.   
The beneficial effect of ACEi in 500 Japanese children with IgAN was reported in a 
retrospective study where cohorts from the years 1976-89 and 1990-2004 were compared. 
The  renal survival of these patients has improved since 1990, with the introduction of 
ACEi [119].  
The use of corticosteroids alone or in combination with cytotoxic agents 
(Cyclophosphamide/Azatioprine or Cyclosporin A) and treatment with cytotoxic agents 
alone has been evaluated in a systematic review including 13 randomized controlled studies 
with over 600 adult patients [120]. All three subsets were each compared to 
controls/placebo/no treatment. The result shows that the use of steroids to high risk patients 
lower the risk of ESRD compared to controls/placebo/no treatment. The use of steroids 
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combined with cytotoxic agents or cytotoxic agents alone did not. However, the reports 
concluded that the examined populations were too small and did not meet methodological 
quality for certainty of the results.  
One of the most referred adult randomized controlled study (Pozzi et al), with a follow-up 
time of more than 15 years, compared the effectiveness of steroid treatment (iv and oral 
during 6 months) with supportive therapy including ACEi or ARB [121, 122]. The 10-year 
renal survival was significantly better and the protein excretion was significantly reduced in 
the steroid treated group compared to the group with supportive treatment.  
There is an on-going debate among paediatric nephrologists on which patient group that 
will benefit from steroid treatment, and if there is sufficient evidence to recommend 
additional immunosuppression. With the expanding use in the 1990s of corticosteroids and 
immunosuppressive drugs in diffuse proliferative IgAN, many observation studies but few 
trials, have been reported in childhood IgAN. The overall level of evidence is low [112]. 
The results of the three largest trials are summarized in Table 11. 
 
Study N 
treatment Proteinuria GFR decline 
Histology 
deterioration       Yoshikawa [124] 80 1.Pred+AZA+ anticoagulation 2. pred alone 
More reduced in 1 No difference No increase in 1 but in 2 
Hogg [125] 96 1.Pred 2. OmegaIII 3. placebo 
No benefit of treatment 1 or 2 versus 3 No benefit of treatment 1 or 2 versus 3 Not evaluated 
Coppo [118] 66  (32 children) 
1.ACEi 2.placebo Significant reduction in 1 Trend effect Not evaluated 
 
Table 11. Result of trials in paediatric IgAN , adapted after Coppo et al [39].  
AZA= azatioprine, pred=prednisolone, ACEi=angiotensin converting enzyme inhibitor 
 
In a Japanese study [124] the effect of steroids in combination with Azatioprine and 
anticoagulants was compared with the effect of steroids alone. The regimen was given for 2 
years to patients with diffuse mesangial proliferation. The result favoured the combined 
therapy, which was more efficient in reducing proteinuria and preventing 
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glomerulosclerosis. RAAS blockade was not used in the referred study. The side effects of 
the treatment in the referred study, which were also used in and earlier large Japanese 
randomized controlled study, were few [123,124]. 
A recent multicentre-study has evaluated the effect of prednisolone with placebo and 
omega III [125]. Ninety-six children with biopsy proven IgAN, GFR > 50 ml/min/1.73m2 
and moderate to severe proteinuria, were randomly assigned to one of the treatments for 2 
years. In group 1, prednisone with the dose tapered from 60 mg/m2 BSA. Group 2 received 
Omega III and group 3 was given placebo. Hypertensive patients were given ACEi. The 
results showed no benefit neither from steroid therapy or omega III compared to placebo, 
when the outcome was defined as GFR < 60 % of baseline and no difference in proteinuria. 
Other studies with Omega III have shown conflicting results and at present time there is not 
sufficient evidence for treatment recommendations [118, 126]. 
  
 25 
 
 
5.4 Predictors of outcome in patients with HSN  
Results of study III 
We summarize the predictors of a poor outcome in a study group of 78 patients with mean 
5.2 up to 17 years of follow-up. The cohort includes patients with mild as well as severe 
(41%) features at first visit, and with biopsies showing mild and advanced (64%) histology 
findings (Table 8 and 9). Twenty patients (26%) progressed to poor outcome defined as 
active renal disease or CKD stage 4-5/ESRD (Table 10). Both severe clinical features at 
onset and advanced biopsy findings were related to a poor outcome. The frequency of 
patients with poor outcome in relation to symptoms at onset is in the same range as in 
studies of the same size showed in Table 3. 
The clinical independent predictors of a poor outcome were assessed in the univariate 
analysis. They were high age at onset, high levels of proteinuria at one year follow-up, 
severe clinical features at onset and high systolic blood pressure. Of the histology 
predictors the amount of mesangial proliferation, mesangial matrix expansion, interstitial 
inflammation and interstitial fibrosis were found to discriminate between good and poor 
prognosis. Multivariate analysis showed that the combination of proteinuria at one year and 
the ISKDC grading gave the highest predictive power. The cut-off level of proteinuria at 
one year follow-up predicting a poor outcome was as low as 144 mg/mmol.  
The relationships between clinical and histological findings and the outcome has been 
discussed by several authors [1, 6, 12, 33, 50-56, 83, 91, 93]. Several authors agree that 
patients with nephrotic syndrome or a nephritic-nephrotic picture at onset seem to be of 
highest risk of a poor outcome. In accordance with others [51, 56, 83, 93, 101-104] we 
advocate an early biopsy in patients with nephrotic range proteinuria before the decision of 
the treatment strategy is made (see section 3.3.1). In certain cases of prolonged severe 
symptoms a repeated biopsy can be of value [83]. In our study III patients with nephrotic 
syndrome or a nephritic-nephrotic picture showed a high recovery-rate (59%). Half of the 
patients in this group were treated.    
Our contribution to the previous knowledge in the field is the special attention to patients 
with persistent mild to moderate proteinuria in which 18% of the patients had a poor 
outcome. These observations have also been verified in a recent study of 433 patients [127] 
and in another of 65 patients [128]. The prognostic value of follow-up proteinuria has been 
recognized by others [53, 100] but it has not previously been specified to time or amount. 
Goldstein et al [55] conducted a long-term follow-up of mean 23 years showing that active 
renal disease and renal insufficiency were potential outcomes many years after apparent 
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remission for all forms of clinical presentation. Therefore the prediction by clinical features 
at onset was not reliable in the assessment of the individual patient.  
Many authors have discussed the predictive value of an early biopsy in severe HSN [54-56, 
83, 93, 96]. Several authors state that cellular or fibrocellular crescents carry a prognostic 
significance [1, 6, 33, 36, 56, 91, 98, 100]. The predictive role of crescentic lesions in 
glomerular diseases has been considered unquestionable. However, the definition of 
crescents varies between the studies compared, and in some cases the cellular versus 
fibrous nature of the crescents is not stated. Another source of error is that the distribution 
of crescents is unevenly spread in the biopsy specimen and may give a false impression of 
the glomeruli involved. The risk increases in levels less than 20% crescents [129] . 
 
 Good outcome Poor outcome Summary 
CRE absent 26 4 30 
CRE present 19 10 29 
 45 14 59 
 
Table 12.  
Presence and absence of crescents in relation to outcome in study III 
 
We found no significant difference between presence and absence of crescents in relation to 
outcome (Table 12) which is in concordance with others [53, 87, 88, 127, 130]. Our 
conclusions can be due to the retrospect nature of our study with an inevitable pre-selection 
bias of treated cases. Thirty-eight per cent of all patients in the study group were treated 
which is 47% of the subgroup who were biopsied and 21/29 (72%) of patients with 
crescents. We assume that treatment has improved the course of the disease. However, our 
present outcome data does not show that treatment has a positive effect on outcome. The 
explanation might be that treatment was given to the most severe cases. Figure 7 shows the 
distribution of cellular or fibrocellular crescents in groups of patients with increasing 
amount (absent, < 20%, 20-50% and > 50%), and the proportion of patients with a poor 
outcome in each group (13, 31, 33 and 50% respectively).  
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                  Treated %    27            69               67              100  
Figure 7.  
Distribution of cellular or fibrocellular crescents and their relation to poor 
outcome at the last visit in the 59 biopsied patients with HSN in study III.  
Total number of patients in each histology group (dark)  
Subgroups of patients with poor outcome in each histology group (light) 
The percentage treated patients in each group is shown in the lower part of the figure 
 
Apart from crescents we found active lesions such as mesangial proliferation and mesangial 
matrix expansion as predictors in the univariate analysis. These findings were strongly 
interrelated with crescents (r= 0.35, P= 0.006, r=0.49, P< 0.001 respectively) crescents 
also correlated to interstitial inflammation (r= 0.46, P < 0.001) but not to interstitial fibrosis 
or global glomerulosclerosis. As in adults a poor outcome was associated with 
tubulointerstitial findings [88, 131]. However, in our study the frequency of patients with 
interstitial fibrosis was low (n=10) and the amount of was mild to moderate (grade 1-2) 
with no cases of advanced (grade 3) findings.  
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5.5 Predictors of outcome in paediatric IgAN  
Results of study IV 
The aim of this study was to identify the clinical and histological predictors of a poor 
outcome in paediatric IgAN. Furthermore, we validated the histological predictors of a poor 
outcome, identified in the Oxford classification of 265 patients (59 children) [42, 43], 
applied to our cohort of 99 children. Ninety biopsies were available for re-evaluation 
according to the Oxford MEST score (section 1.4.2). Our inclusion criteria and the clinical 
findings at biopsy and at follow-up differed in several aspects compared to the international 
study. The comparisons are shown in Table 13. The end points were identically defined in 
our and the referred study. Poor outcome was defined as a reduction of GFR at the last 
investigation of more than 50% GFR at the time of biopsy or ESRD. 
 
           Oxford study                    Present  study      
  adults children 
            n=206 n=59 n=99 
 
At time of biopsy 
Median age (years) 30 13 13 
Female (%)  28 25 41 
Follow up time (years) 6.4 5.1 13 
Follow up time < 1 year (%) 0 0   4 
Normal GFR at biopsy (%) 77 - 72 
GFR stage 4-5 at biopsy (%) 0 0   5 
Nephrotic (%)  30 27 12 
Microalbuminuric (%) - - 43 
Hypertensive (%) 31 151 302 
Median time to biopsy (mths) 9 2 19 
At follow-up 
RAAS blockade (%) 80 56 24 
Immunosuppression (%)  23 47 11 
Rate of decline of GFR  
 (ml/min/1.73m2/year) -3.7 ± 6.6 -2.7 ± 1.1        -2.0 ± 183 
>50% decline of GFR (%)              22 (all)    3 
ESRD (%)               13 (all)  15 
 
Table 13.  
Clinical findings comparing patients in study IV to the international study [42-
43, 47].  
1 Blood pressure adjusted to adult value > 130/90 (MAP s.d. score >1 using age and gender specific constants) 
 or number of patients taking antihypertensive medication [42] 2 Definition of hypertension, see section 3.4 
3 Excluding outliers; four patients with GFR deterioration > 50 ml/min/1.73m2/year 
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In study IV the individual clinical predictors of a poor outcome were an impaired GFR at 
biopsy and during follow-up at 1, 3 and 5 years, a high blood pressure at biopsy, and a high 
amount of proteinuria at biopsy and during follow-up. Proteinuria at biopsy was identified 
as the strongest predictor (HR 2.31, 95% CI 1.66-3.20). We found that the higher level of 
proteinuria at biopsy, the higher the risk of a poor prognosis. The identification of these 
clinical prognostic markers is in concordance with other authors [14, 18, 57, 62, 132-135], 
with focus on proteinuria as being the strongest. The increased risk of a poor prognosis also 
in patients with moderate proteinuria at biopsy has been discussed [113, 136]. The search 
for predictors in several studies has focused both on levels of proteinuria at biopsy, but also 
on the predictive value of follow-up proteinuria [14, 134].  
Thirty per cent of our patients were hypertensive at time of the biopsy. High blood pressure 
was identified as a predictor only at time of biopsy and not during follow-up. Compared to 
adult series hypertension is less frequently a predictor among children with IgAN. The 
frequency of high blood pressure is often lower in children [65, 137] and is often reversible 
in children compare to adults with IgAN [48].  
In the identification of the histological predictors of a poor outcome we support the 
conclusions in the Oxford classification [42]. We found three out of the four histology 
lesions in the Oxford MEST score to be predictive of a poor prognosis: A high mesangial 
proliferation score (M), presence of endocapillary hypercellularity (E) and a high amount of 
tubular atrophy/interstitial fibrosis (TA/IF), but presence of segmental sclerosis (S) did not 
reach significance in our study. We additionally found presence of cellular or fibrocellular 
crescents and presence of global glomerulosclerosis to be predictive in the univariate 
analysis. Although a small sample size, we identified endocapillary hypercellularity as a 
strong predictor (HR 7.15, 95% CI 2.21-23.13), which was not the case in the referred 
study. Tubular atrophy/interstitial fibrosis was a strong independent predictor in our study, 
which is in concordance with the international study and other authors [14, 47, 138]. This 
lesion correlated strongly to global glomerulosclerosis (r= 0.83) in our and in the 
international study. The discriminative ability of all histology lesions was reduced when 
they were compared with proteinuira at biopsy (Model A), indicating that the influence of 
proteinuria was strong. When histology was combined with proteinuria at one year follow-
up (Model B), the discriminative power of the histology lesion was more pronounced, due 
to a smaller sample size and a selection of the more severe cases. A low GFR at biopsy and 
during follow -up indicated an unfavourable prognosis in the univariate analysis, but not in 
the multivariate analysis. Thus, according to our results, biopsy findings were not 
independent of the impact of clinical data in the prognostic assessment which was found in 
the international study. However, due to the low number of events (n=18) we could not 
expand the multivariate models further. 
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CONCLUDING REMARKS AND FUTURE PERSPECTIVE   
In summary the clinical course of HSN is unpredictable, which requires close monitoring 
and a long-term follow-up. Risk patients are those with severe symptoms at onset and those 
with persistent mild-moderate proteinuria at onset, as well as those with proteinuria at 
follow-up. The clinical picture at onset and the grading of the histological findings as well 
as the amount of proteinuria at follow-up are powerful predictors of a poor prognosis, 
highly informative value for the decision regarding treatment.  
In paediatric IgAN the clinical course is as serious as in adults, with a high risk of disease 
progression. Impaired GFR and the amount of proteinuria at biopsy and during follow-up 
were identified as individual clinical predictors. We support the prognostic significance of 
the histological findings defined in the Oxford classification MEST score. We found three 
out of four lesions to be of prognostic importance; mesangial and endocapillary 
hypercellularity and tubular atrophy/interstitial fibrosis. Additionally we found 
cellular/fibrocellular crescents and glomerulosclerosis to be predictive.  
Identification of reliable clinical and histopathologic prognostic factors in HSN and IgAN 
may contribute to permit an appropriate design for future therapeutic prospective studies. 
There is a need for an evaluation of the long-term effect of ACEi/ARB treatment in mild 
and moderately severe HSN, and further studies are needed to evaluate the efficacy of 
different immunosuppressive drugs in treating severe HSN and IgAN. Large prospective 
longitudinal multicentre studies with strict and narrow inclusion criterias, strict protocols 
for medical interventions and a close follow-up are needed, to evaluate the outcome among 
patients with a similar degree of severity of disease. The objective should be to replace the 
present variety of treatments with more formalized recommendations.  
In the future treatment strategies will most likely focus on the defects in the IgA1 
glycosylation, and the prevention of the mesangial depositions of the IgA complex. 
Moreover, with expanding knowledge about the components of the glomerular barrier and 
its conditions and mechanisms of permeability, a new therapeutic treatment may emerge. 
 31 
 
SVENSK SAMMANFATTNING 
 
Henoch Schönlein Nefrit (HSN) och IgA nefropati (IgAN) diagnosticeras i njurvävnadsprov med 
fynd av IgA depositioner i njurvävnaden i kombination specifika avvikelser talande för 
sjukdomsutveckling sekundär till denna deposition. Sjukdomarna har olika långtidsförlopp: HSN 
anses vara en akut sjukdom med multi-organ engagemang (hud, leder och magtarmkanal) och 
vanligtvis ett spontant läkningsförlopp och generellt en god prognos. IgAN beskrivs däremot som en 
kronisk sjukdom med en långsam progress och hög risk för utveckling av kronisk njursjukdom. 
Förloppet och prognosen för de båda sjukdomarna är emellertid svårt att förutsäga. Syftet med 
avhandlingsarbetet är att öka kunskaper och identifiera riskfaktorer för sjukdomsprogress och dålig 
prognos bland HSN och IgA patienter samt att studera effekten av behandling till de svåra fallen. I 
studie I sammanställdes resultat från 73 HSN patienter. Sambanden mellan klinik och histologi 
studerades. Klinisk bild vid symtomdebut (grad av proteinutsöndring (proteinuri) och resultat av 
njurfunktion (GFR) undersökning) jämfördes med resultat av njurvävnadsprov (njurbiopsi). Patienter 
med uttalad proteinuri (nefrotisk) hade ofta förekommande avancerade patologiska förändringar och 
nedsatt GFR. Avancerad njurpatologi förekom även i hög frekvens bland patienter med lägre nivå av 
proteinuri (icke-nefrotisk). Proteinnivå ökade och GFR nivån minskade med ökad grad av patologi i 
njurbiopsin. I studie II studerades behandlingseffekt vid svår sjukdom (n=43, 24 HSN, 19 IgAN). 
Grupp A, n=18, fick behandling med kortison och ytterligare immunhämmande läkemedel 
(Cyklofosfamid) samt proteinreducerande läkemedel (RAAS blockad). Av de 25 patienterna i grupp 
B fick 15 kortison och RAAS blockad och övriga 10 endast RAAS blockad. Graden av proteinuri 
minskade efter behandling med kortison och ytterligare efter behandling med Cyklofosfamid i grupp 
A. GFR förbättras vid uppföljning under median 3 år, upp till 10 år. Proteinurin minskade även efter 
behandling i grupp B och GFR nivån var stabil under uppföljning. Markörer för utveckling av dålig 
prognos bland 78 HSN patienter identifierades i studie III. Dålig prognos definierades som 
kvarvarande aktiv njursjukdom alternativ kronisk njursjukdom med GFR ≤ 30 ml/min/1.73m2 
alternativ terminal njursvikt som kräver dialys eller transplantation. Riskfaktorer för utveckling av 
dålig prognos var hög ålder vid debut, svår klinisk bild vid debut, hög grad av proteinuri vid ett års 
uppföljning samt hög grad avancerade förändringar i njurbiopsi. Nivån av proteinuri vid ett års 
uppföljning i kombination med graden njurvävnadsskada utgjorde tillsammans den bästa 
möjligheten att förutsäga dålig prognos. Det prognostiska värdet av en ny klassifikation för IgAN 
(Oxfordklassifikationen) samt betydelsen av och sambandet med kliniska parametrar studerades i 
studie IV. 99 IgA patienter följdes under medel 13 år och 90/99 biopsier bedömdes enligt 
Oxfordklassifikationens s.k MEST score baserat på fyra njurvävnadsfynd som ansågs vara 
prognostiskt ogynnsamma. Nedsatt GFR, högt blodtryck vid biopsi och hög nivå av proteinuri både 
vid biopsi och under uppföljning identifierades som kliniska markörer för dålig prognos. Tre av de 
fyra njurvävnadsfynden i MEST score visade sig ha prognostisk betydelse. 
Slutsatser av detta arbete kan bidra till kunskap för omhändertagandet av pediatriska HSN och IgA 
patienter, så att medicinska insatser till de svåra fallen kan förhindra eller förskjuta utvecklingen av 
kronisk njursjukdom. 
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Abstract We evaluated the renal hemodynamics and the
urine protein excretion rates of 73 children with Henoch-
Sch�nlein nephritis (HSN). In 40 children we also per-
formed a renal biopsy. The glomerular filtration rate
(GFR) and effective renal plasma flow were determined
by the clearances of inulin and para-aminohippurate
during water diuresis. Urine albumin and IgG excretion
were assessed in short-term timed samples. The mean
GFR at the first examination was reduced in the HSN
patients and most reduced in those with nephrotic pro-
teinuria. There was an inverse correlation between the
GFR at the first examination and the amount of albu-
minuria and urinary IgG excretion. Among the 40 patients
with some degree of proteinuria who underwent a renal
biopsy, 9 of 13 patients with mild to moderate proteinuria
had severe morphological changes. GFR correlated in-
versely and fractional albumin and IgG excretion directly
with the severity of the pathological findings on the bi-
opsy, and with segmental and global sclerosis, the grade
of mesangial proliferation, and interstitial inflammation.
In conclusion, GFR is moderately reduced early in HSN
and more reduced in patients with more proteinuria and in
those with more advanced morphological changes.
Moreover, even mild to moderate proteinuria may indi-
cate severe morphological changes, which increase the
indications for early renal biopsy in these patients.
Keywords Henoch-Sch�nlein glomerulonephritis ·
Glomerular filtration rate · Renal hemodynamics ·
Proteinuria · Albuminuria · Urinary IgG · Renal
morphology
Introduction
Henoch-Sch�nlein purpura (HSP) is the most common
systemic vasculitis in childhood. In the United Kingdom,
the incidence is 14–20 per 100,000 children per year and
the estimated annual incidence is highest between 4 and
6 years of age [1, 2]. Skin biopsy shows a leukocytoclastic
vasculitis that involves the small vessels. The vasculitis
may affect several organ systems, but mainly affects the
skin, joints, gastrointestinal tract, and kidneys. Glomeru-
lonephritis (HSN), the principal manifestation of HSP,
occurs in 40%–50% of cases [3]. Many authors have
shown an association between the renal symptoms at
onset and the long-term outcome [4]. We therefore
wished to study further how the clinical findings at onset
of HSN are related to renal function and to the histolog-
ical changes in a renal biopsy performed within 5 years of
onset of the disease. We also investigated how the pro-
teinuria was related to renal hemodynamics and to the
biopsy findings.
Materials and methods
Between 1975 and 2002, we studied 73 children with HSN, 32
boys, with a median age of 8.1 (2.0–16.6) years at the onset of the
disease. The clinic has a regional population of 100,000 children
between 0 and 18 years of age and a catchment area that includes
greater Stockholm and patients from other parts of Sweden. Our
hospital is one of two referral hospitals in Sweden for children with
kidney diseases. Nearly all those from our referral area (i.e., about
two-thirds of Swedish children), who need a kidney biopsy, are
referred to us. The patients were referred at various stages of the
disease and they were divided into five groups, according to their
clinical findings at onset. The first group of patients had only he-
maturia (HEM) at onset. The second group had proteinuria (PROT)
with macro- or microscopic hematuria. The third group had the
acute nephritic syndrome (AN) with hypertension and/or an in-
crease in the serum creatinine level and hematuria with or without
proteinuria. The fourth group had the nephrotic syndrome (NS)
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with proteinuria >40 mg/m2 per hour and a serum albumin level
below 25 g/l with or without edema. The fifth group of patients had
a mixed nephritic-nephrotic (AN+NS) picture at onset.
On admission, the urinary protein excretion rate, blood pressure,
and serum creatinine concentration were determined in the children
and hemodynamic studies were performed. The median duration of
the disease at the first examination was 0.48 (0.01–3.0) years. Renal
hemodynamics were assessed by the glomerular filtration rate
(GFR) and effective renal plasma flow (ERPF) determined by the
clearances of inulin and para-aminohippuric acid during water di-
uresis, using a standard clearance technique with continuous infu-
sion and repeated urine sampling [5]. The filtration fraction (FF)
was calculated as the ratio between GFR and ERPF. The control
group for renal function comprised 49 healthy children aged
9.9€4.5 years. The GFR of the control group was 116€11 ml/min
per 1.73 m2, the ERPF was 611€90 ml/min per 1.73 m2, and the FF
19.3€2.5%.
At the time when the renal function study was performed, we
collected a short-term timed urine sample and a serum sample for
analysis of albumin, IgG, b2-microglobulin, and creatinine in both
blood and urine. The detection level of albuminuria was 4 mg/l.
The ratios of urinary albumin/creatinine (Ualb/UCr) (mg/mmol)
and urinary IgG/creatinine (UIgG/UCr) (mg/mmol) were calculat-
ed. Since the range of Ualb/UCr was large and not normally dis-
tributed, the ratio was log-transformed. Microalbuminuria was de-
fined as Ualb/UCr of 2.5–25 mg/mmol [6], which corresponds to
log Ualb/UCr of 0.4–1.4. Nephrotic proteinuria was defined as
Ualb/UCr �400, which corresponds to log Ualb/UCr �2.6.
Hypertension was defined in accordance with the Task Force
Report on High Blood Pressure in Children and Adolescents [7].
Two patients were treated with enalapril at a low dose at the time of
biopsy. Three patients had been treated with low doses of oral
corticosteroids (1 mg/kg) for 1 or 2 weeks, respectively, prior to the
biopsy due to bowel pain.
Renal biopsy was performed in 40 children within 5 years of the
onset of their disease. The biopsies were performed 0.04–4.9
(median 0.7) years from the onset. Some AN and/or NS patients
entered a spontaneous remission without an early biopsy, which
explains the wide time range. In the PROT group the median time
for the biopsy was 2.1 years, while in the two nephrotic groups (NS
and AN+NS) the median time was 0.08 and 0.12 years, respec-
tively. The indication for renal biopsy was based on the clinical
findings. The patients were sedated with midazolam and morphine
and were given lidocaine local anesthesia. The biopsy was per-
formed percutaneously, under ultrasound guidance, using an auto-
matic device with a 16-gauge needle (Bard Magnum Biopsy In-
strument and Core Tissue Biopsy Needle, Urological, Covington,
Calif., USA). Specimens were taken for light microscopy (LM) and
immunofluorescence (IF). The biopsies were fixed in 4% parafor-
maldehyde in phosphate buffer. All patients showed predominantly
IgA with IF. In this paper, we discuss only the LM results.
The degree of glomerular involvement was determined by cal-
culating the total number of glomeruli and then the percentages of
glomeruli with global or segmental sclerosis and of glomeruli with
crescents. Signs of mesangial matrix expansion, mesangial prolif-
eration, interstitial inflammation, and interstitial fibrosis with tu-
bular atrophy were noted and semi-quantitatively graded on a four-
point scale (0–3). All biopsy findings were then classified on a five-
point scale (I–V) as recommended by the International Study of
Kidney Disease in Children (ISKDC) [8]. The study protocol was
approved by the Ethics Committee of Karolinska Institutet at
Huddinge University Hospital.
Statistical analysis
The data are expressed as mean values€1 standard deviation (SD) if
they were normally distributed. Statistical comparison of patient
groups was performed using ANOVA with the post hoc Tukey test.
Spearman rank correlations were used to assess the relationship
between renal hemodynamics and proteinuria with various biopsy
parameters. The statistical program of Statistica 6.0 was used.
P<0.05 was chosen as the level of significance.
Results
On the first investigation, the mean GFR of all 73 HSN
patients was 103€25 ml/min per 1.73 m2 and the FF
18.0€3.5%, which is significantly lower than the results
of the controls (Table 1). The ERPF was similar to the
controls.
Table 1 shows the clinical findings at onset and the
renal hemodynamics at the first investigation. The GFR
differed in the five groups at the first investigation (Fig. 1
and Table 1). It was normal in the HEM group and low in
the other groups, being lowest in the NS and AN+NS
groups, in whom 50% and 70%, respectively, had GFR
below –2 SD of that of the controls. In the PROT group,
the GFR was only moderately reduced and differed from
the AN+NS group. The ERPF was similar in all the
groups. The FF was significantly lower in the AN+NS
group than in controls and in the HEM and PROT groups.
The FF in the NS group differed significantly from that in
the HEM group. We found no gender differences in GFR
in the various clinical groups.
Figure 2 shows the GFR in relation to the degree of
albuminuria at the time of the first renal functional ex-
amination. The GFR was significantly higher in patients
with normo- and microalbuminuria than in those with
albuminuria in the nephrotic range. There were 8% of
patients with microalbuminuria that had GFR below –
2 SD, compared with 66 % in the group of patients with
nephrotic proteinuria. Moreover, there was an inverse
correlation between log Ualb/UCr and GFR (r=�0.55,
Table 1 Relationship between
clinical findings at onset and
renal hemodynamics
(mean€SD) (GFR glomerular
filtration rate, ERPF effective
renal plasma flow, FF filtration
fraction)
n GFR ERPF FF
(ml/min per 1.73 m2) (%)
1. Hematuria (HEM) 12 118€20 572€69 20.8€3.2*1, *2
2. Proteinuria€hematuria (PROT) 27 108€18 573€126 19.9€2.9*3
3. Acute nephritic syndrome (AN) 17 106€26 588€132 18.0€3.5
4. Nephrotic syndrome (NS) 6 88€27 603€140 14.7€3.3
5. Nephritic/nephrotic (AN+NS) 11 79€26 585€99 14.6€2.5*4
Total number of patients 73 103€25*5 580€115 18.0€3.5*6
Controls 49 116€11 611€90 19.3€2.5
*1 P=0.003 vs. NS, *2 P=0.0001 vs. AN+NS, *3 P=0.005 vs. AN+NS, *4 P=0.003 vs. controls,
*5 P=0.002 vs. controls, *6 P =0.048 vs. controls
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n=44, P=0.0001) and between UIgG/UCr and GFR
(r=�0.53, n=33, P=0.0014) at the time of the first inves-
tigation.
Table 2 shows the clinical findings at the onset in
relation to the renal biopsy changes, which were graded
according to the ISKDC. The biopsies were taken from 40
patients in groups 2–5 with no patients from group 1
(hematuria only). The most common histological changes
were grade III (mesangial proliferation with crescents or
glomerular sclerosis in <50% of the glomeruli), seen in 19
of 40 (47%) of the biopsies; 6 of 40 (15%) patients had
grade IV (mesangial proliferation with crescents and/or
glomerulosclerosis 50%–75%) and 2 of 40 (5%) had
grade V (mesangial proliferation with crescents or glo-
merulosclerosis >75%). Thus 68% of all biopsies showed
grade III changes or more. In the PROT group, 13 of 27
(48%) were biopsied and 9 of 13 (69%) of the biopsies
had grade III or more changes, compared with 58% in the
AN group, 60% in the NS group, and 70% in the AN+NS
group. There was no statistically significant difference in
proteinuria between the biopsied and the non-biopsied
patients in the PROT group. The STAT exact test showed
no statistically significant difference between the clinical
findings at onset and the biopsy findings.
The GFR was significantly lower in patients with
crescents (80€26 ml/min per 1.73 m2) than in those
without (111€20 ml/min per 1.73 m2, P=0.0002). Those
with crescents had more proteinuria, measured as log
Ualb/UCr and UIgG/UCr, than those without (P=0.00014
and P=0.011, respectively). In patients with global and
segmental sclerosis, we found inverse correlations be-
tween the percentages of glomeruli with global and seg-
mental sclerosis and GFR (r=�0.637, n=13, P=0.019 and
r=�0.489, n=22, P=0.021, respectively). Figure 3a shows
the GFR in 36 patients from the various ISKDC groups at
the time of the biopsies. Renal hemodynamics were not
studied in 4 patients at the time of the biopsy. The GFR
deteriorates with more advanced pathological findings,
i.e., it was significantly lower in those with grade IV
changes than in the controls and those with grade I
changes. Figure 3b and c shows log Ualb/UCr and UIgG/
UCr in the ISKDC groups. Albuminuria and urinary IgG
excretion increased with more advanced pathology on the
biopsies (Table 3). Figure 3b also shows that all patients,
except one with ISKDC grades IV and V changes, had
proteinuria in the nephrotic range.
Table 3 shows the significant correlation coefficients
between the biopsy findings and the GFR, log Ualb/UCr,
UIgG/UCr, systolic and mean arterial blood pressure
(MAP). The correlations with proteinuria were calculated
only in patients with measurable urinary albumin and
urinary IgG levels, respectively, at the time of the biopsy.
We found decreases in the GFR and increases in the
fractional albumin and IgG excretion with increasing
grades of interstitial inflammation, mesangial prolifera-
tion, and ISKDC groups on the biopsy.
An inverse correlation was noted between the GFR at
the time of the biopsy and log Ualb/UCr and UIgG/UCr,
respectively (r=�0.570, n=31, P=0.0008 and r=�0.518,
n=23, P=0.011), but no significant correlation between
Fig. 2 GFR (ml/min per 1.73 m2) on the first investigation in re-
lation to normoalbuminuria (Ualb/UCr <2.5), microalbuminuria
(Ualb/UCr 2.5–25), albuminuria (Ualb/UCr >25–400), and albu-
minuria in the nephrotic range (Ualb/UCr >400 mg/mmol). The
dotted lines indicate €2 SD of those of the controls. The number of
patients is given in the lower part of the figure
Table 2 ISKDC grading of the renal biopsies in the patients who
were grouped according to their clinical symptoms at onset
n Grade
I II III IV V
1. HEM 0
2. PROT 13 1 3 7 1 1
3. AN 12 3 2 6 1 0
4. NS 5 0 2 2 1 0
5. AN+NS 10 1 1 4 3 1
Total 40 5 8 19 6 2
Fig. 1 Glomerular filtration rate (GFR) (ml/min per 1.73 m2) on
the first investigation of the patient groups according to their
clinical findings at onset. The number of patients is given in the
lower part of the figure (HEM) hematuria, PROT proteinuria€he-
maturia, AN acute nephritic syndrome, NS nephrotic syndrome, Co
controls)
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Ub2/UCr and the biopsy findings. Direct correlations
were detected between the systolic blood pressure or
MAP and the ISKDC grading and mesangial proliferation
(Table 3). None of the blood pressure data were matched
Fig. 3 a GFR (ml/min per 1.73 m2) at the time of the biopsy in the
various groups. The dotted lines indicate €2 SD of those of the
controls. The number of patients is given in the lower part of the
figure. b Proteinuria (log Ualb/UCr) at the time of the biopsy in the
various groups. The dotted lines indicate the ranges of microalbu-
minuria and albuminuria. The number of patients with measurable
Ualb is given in the lower part of the figure. c Proteinuria (UIgG/
UCr) at the time of the biopsy in the various groups. The number of
patients with measurable UIgG is given in the upper part of the
figure
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for age or length, but the mean ages of the patients in the
various biopsy groups were similar.
Discussion
The aim of this study was to evaluate the relationship
between the clinical findings at onset and (1) the renal
function and (2) histological findings in HSN patients
biopsied within 5 years of disease onset. The two main
findings were that HSN patients as a group had a lower
GFR at the first examination than controls and that severe
morphological changes occurred not only in patients with
proteinuria in the nephrotic range, but also in those with
mild proteinuria (Ualb/Cr 25–400 mg/mmol). Thus the
clinical findings at the onset of the disease cannot predict
the morphological changes. Moreover, the more severe
the morphological changes, the greater the proteinuria,
the lower the GFR, and the higher the blood pressure at
the time of the biopsy. Among the pathological findings
in the biopsy, the percentage of global and segmental
sclerosis, mesangial proliferation, and interstitial inflam-
mation seemed to correlate best with poor renal function,
albuminuria, and IgG excretion.
Our patients are both selected and unselected, since
those from our area had all stages of the disease, and most
had mild renal involvement. Many patients with more
advanced stages of the disease were referred to us from
other parts of the country for a renal biopsy. In our study,
34 of 73 (47%) of the patients had AN, NS, or AN+NS at
the onset. The distribution of our study population
therefore differs from that of Koskimies et al. [9], who
reported 27% with AN, NS, or AN+NS among 29 unse-
lected HSN patients.
The lower GFR found in the entire HSN group re-
sembles that in previous studies on children with IgA
nephropathy from our unit [10, 11]. The normal GFR in
the HEM group may indicate a good prognosis. This is in
accordance with the findings of others who reported that
fewer than 5% developed renal failure in this group [4, 9,
12]. Patients in the PROT group had a slightly reduced
GFR, despite the high proportion of severe morphological
changes. The inverse correlation between GFR and al-
buminuria in the present study resembles our findings in
children with IgA nephropathy [11]. Coppo et al. [13]
compared the prognosis of HSN in adults with that of
children and found no definite level of proteinuria in
children that was associated with a poor prognosis.
However, the clinical outcome in children with absent or
mild proteinuria was usually better than in those with
higher levels of proteinuria, but the difference was not
statistically significant. Therefore the clinical course was
more unpredictable in children than in adults [13]. We
found the lowest GFR in the NS and AN+NS groups,
which accords with the findings of Sch�rer et al. [14],
who reported that the presence of renal insufficiency or
NS at the onset predicts the development of chronic renal
disease. The lower GFR in our patients with crescents
than in those without also agrees with the results of
Sch�rer et al. [14], who found that patients with crescentic
glomerulonephritis had a poor prognosis.
Of 40 biopsies, 68% had histological findings of grade
III changes or greater. However, one should remember
that none of the patients from the HEM group underwent
a biopsy. Our study shows that proteinuria at the onset is
frequently associated with advanced renal pathology. The
log Ualb/UCr and UIgG/UCr correlated with the ISKDC
grade in the biopsy. In groups ISKDC III–V, 10 of 24
(41%) and in groups IV–V, 7 of 8 (87%) of the patients
had proteinuria in the nephrotic range at the time of the
biopsy. Patients with nephrotic or nephritic-nephrotic
findings at the onset, and those with a high proportion of
crescents in the renal biopsy, may have a poor prognosis
[13, 15, 16, 17, 18]. Our study shows that a renal biopsy is
indicated not only in patients with nephrotic symptoms,
but also in those with mild proteinuria. The amount of
proteinuria should be closely monitored and if severe or
the nephrotic syndrome develops, the biopsy must be
performed immediately to decide whether treatment is
necessary. Several protocols have been used but there is
no golden standard [19, 20, 21]. Renal function can de-
teriorate many years after signs of recovery and the pa-
tients therefore need a long-term follow-up [4].
In our study the proteinuria correlated with the ISKDC
grade. The log Ualb/UCr and UIgG/UCr correlated with
both glomerular mesangial proliferation and interstitial
inflammation. The main risk factor for progression of
glomerular disease is the severity of the proteinuria [22].
This is shown by the selectivity index (SI) based on the
ratio of IgG to transferrin clearances. The SI correlated
with the severity of the histological lesions in patients
with glomerular diseases [23, 24]. Patients with high or
moderately selective proteinuria showed less severe
tubulointerstitial damage than those with non-selective
proteinuria. According to D’Amico and Bazzi [24], the
fractional urinary excretion of IgG correlated with the
tubulointerstitial damage, but not with the glomerulo-
sclerosis. In the present study, we found a correlation
between UIgG/UCr and interstitial inflammation, but no
correlation with interstitial fibrosis, probably because of
the short time elapsed between the onset and the biopsy.
We also found higher blood pressure in patients with
more severe morphological changes. Yoshikawa et al.
[18] reported that patients presenting with hypertension
and/or acute renal insufficiency were more likely to de-
velop chronic renal failure, while Sch�rer et al. [14] in a
multivariate regression analysis could not show that initial
hypertension was a significant predictor of a poor out-
come. Coppo et al. [13] found that, in contrast to adults,
no definite level of proteinuria or hypertension was as-
sociated with a poor prognosis in children.
To summarize, we noted that more advanced mor-
phological lesions in the renal biopsy were reflected by a
lower GFR and more marked proteinuria. The GFR was
lower in HSN patients as a group than in the controls, and
especially in those with nephrotic syndrome at the onset
or advanced biopsy findings. Our study clearly shows that
proteinuria is a marker of renal damage in HSN. In pa-
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tients with non-nephrotic proteinuria at the onset, we
found severe histological changes in 9 of 13 biopsies,
despite only a moderate reduction in the GFR. Thus pa-
tients with HSN should be followed both by determining
GFR and fractional protein excretion rates, and those with
persistent proteinuria need an early kidney biopsy. These
findings increase the understanding of risk factors pre-
dicting a poor prognosis in HSN, although a longer fol-
low-up is needed to obtain more conclusive results.
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Abstract Our aim was to report the effect of two treatment
regimens in 43 cases of severe Henoch–Schönlein nephritis
(HSN) and immunoglobulin A nephritis (IgAN) (24 HSN,
19 IgAN). Group A, 11 HSN and 7 IgAN, 88% with an
International Study of Kidney Disease in Children (ISKDC)
biopsy grade ≥ III and severe clinical features, were treated
with corticosteroids, cyclophosphamide (CYC-P) and
angiotensin-converting enzyme inhibitor/angiotensin recep-
tor blocker (ACEi/ARB). Group B, 12 HSN and 13 IgAN,
72% with biopsy findings as above and 52% with severe
clinical features, were treated with ACEi/ARB ± cortico-
steroids. The outcome classification was: (a) healthy; (b)
mild proteinuria, normal glomerular filtration rate (GFR);
(c) active renal disease; (d) chronic renal failure. Twenty-
six patients had a good outcome (a+b). The 17 children
with poor outcome (c+d) had lower GFR at onset and at
follow-up, higher albumin excretion at follow-up, and
higher percentage of segmental glomerulosclerosis in the
renal biopsy, than those with good outcome. Treatment with
corticosteroids, CYC-P and ACEi/ARB was effective in
increasing GFR, reducing proteinuria and decreasing the
disease activity index. The proteinuria had decreased at
follow-up in both groups. In group A, GFR increased and
histopathological activity index declined after treatment.
The outcome did not differ between groups A and B. The
effects of treatment did not differ between HSN and IgAN.
Keywords Methylprednisolone . Cyclophosphamide .
Renal biopsy findings . Proteinuria .
Glomerular filtration rate . Segmental glomerulosclerosis .
IgA nephritis . Henoch–Schönlein nephritis
Introduction
The management of severe Henoch–Schönlein nephritis
(HSN) and immunoglobulin A nephritis (IgAN) is still
controversial. Severe cases are rare, but the morbidity rate
among these patients is high. Severe disease is defined
according to the clinical features and duration of proteinuria
[1] and renal biopsy findings showing a high proportion of
glomeruli with crescents or sclerosis as well as interstitial
inflammation or fibrosis [2–5].
Various regimens of treatment in severe HSN and IgAN
have been described, such as intravenous administration
of methylprednisolone (MP) followed by oral treatment
with corticosteroids, or corticosteroids in combination with
azathioprine (AZA) or cyclophosphamide (CYC-P), with or
without anticoagulants, with or without plasmapheresis,
cyclosporine A (CyA) or mycophenolate mofetil [6–21].
Treatment with angiotensin-converting enzyme inhibitors
(ACEis) [22] with or without the combination of angioten-
sin II receptor blockers (ARBs) [23] in both normotensive
and hypertensive patients has been shown to be effective in
preserving glomerular filtration rate (GFR) and reducing
proteinuria in IgAN patients.
The aim of this study was to describe the effects of
treatment of two groups of patients. Group A had severe
disease and were treated with corticosteroids in combination
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with CYC-P and ACEi /ARB, whereas group B consisted of
patients both with milder and severe disease. All group B
patients were treated with ACEi/ARB with or without
corticosteroids.
Materials and methods
The study was longitudinal and retrospective. We examined
43 children (25 boys), of whom 24 had HSN (14 boys)
and 19 IgAN (11 boys), admitted to the department of
Pediatric Nephrology at the Karolinska University Hospital,
Hudddinge, between May 1990 and December 2005. Our
clinic is the larger of two tertiary centers for children with
kidney diseases in Sweden. Thus, the patients were mainly
referral patients with a severe clinical presentation at onset.
Their median age at onset was 12.0 (4.1–17.7) years, and they
were followed for a median of 3.1 (0.25–10.5) years. The age
at onset did not differ significantly between the groups.
In Group A there were 18 patients (11 HSN, 7 IgAN), of
whom 17 had renal biopsy findings according to the
International Study of Kidney Disease in Children (ISKDC)
of ≥ grade III, in combination with nephrotic proteinuria at
onset, and all except one had severe clinical features. They
were initially treated intravenously with MP 30 mg/kg for
three alternate days. Twelve patients were also treated
orally with prednisolone at a starting dose of 1 mg/kg daily,
which, 1 month later, was changed to alternate-day dosing
and slowly tapered thereafter. The duration of the oral
treatment with corticosteroids was a median 0.6 (0.4–3.1)
years. After MP, the regimen also included intravenous
treatment with CYC-P 500–750 mg/m2 body surface area,
1–3 pulses (14 patients), or six pulses monthly (2 patients),
or oral administration of CYC-P 2 mg/kg daily for 8 weeks
(2 patients). All patients received ACEis/ARBs.
Group B consisted of 25 patients (13 HSN, 12 IgAN) of
whom12 had severe clinical features. Eighteen patients had
undergone a biopsy showing ISKDC grade ≥ III, but only
five of these 18 had nephrotic proteinuria. Five patients had
biopsy findings showing ISKDC grade II, and two patients
had ISKDC grade I. All 25 patients were treated with
ACEis/ARBs with (15 patients) or without (10 patients)
corticosteroids. The duration of the latter medication was a
median 0.3 (0.02–0.7) years.
The recommendations of treatment have changed over
time. In group A only 3/18 patients had been treated before
1998, compared with 6/25 in group B. At the time,
aggressive treatment with immunosuppression not com-
monly used.
The patients were classified into five categories
according to their renal manifestations at onset and at
biopsy [24]: (1) micro- or macroscopic hematuria; (2)
persistent mild proteinuria (<1 g/l or urine albumin/
creatinine ratio (Ua/c) < 200 mg/mmol) ± hematuria; (3)
nephritic syndrome (moderate proteinuria (Ua/c≥ 200–
400 mg/mmol), decreased GFR, hematuria and/or hyper-
tension [25]); (4) nephrotic syndrome (urinary albumin
excretion >40 mg/h per square meter body surface area or
Ua/c ≥ 400 mg/mmol, serum albumin <25 g/l); (5) mixed
nephritic/nephrotic syndrome at onset. Classes 1 and 2 were
considered as mild clinical features, and classes 3–5 as
severe. Severe features at onset were present in 66% of
group A patients and 48% of group B patients, while, at the
time of the first renal biopsy, the corresponding values were
94% and 48%, respectively.
On admission, all patients had undergone a renal function
test and a renal biopsy at a median 0.2 years after onset. Nine
patients (eight from group A, one from group B; 7/9 HSN,
2/9 IgAN) underwent a second renal biopsy at a median
1.5 years from onset, so that the effect of treatment could be
assessed or because of progression of the disease. The GFR
and effective renal plasma flow (ERPF) were determined by
urinary clearances of inulin and para-amino-hippurate (PAH)
during water diuresis [26]. Fifty children with no renal
disease served as controls (Table 1).
The outcomes were categorized as: (a) normal and minor
urinary abnormalities; this category included both healthy
patients without urinary abnormalities and those with micro-
albuminuria (Ua/c 2.5–25 mg/mmol) with or without
hematuria (b) Persistent mild proteinuria and GFR ≥ 94 ml/
min per 1.73 m2 (two standard deviations below the mean
value of the controls); (c) active renal disease (i.e.
hypertension with mean arterial pressure (MAP) > 95th
percentile and/or Ua/c ≥ 200 mg/mmol and/or GFR 40–
94 ml/min per 1.73 m2; (d) chronic renal failure (CRF)
(GFR ≤ 40 ml/min per 1.73 m2) or end-stage renal disease
(ESRD, requiring dialysis and/or renal transplantation).
Categories a and b were considered as good outcomes and
categories c and d as poor outcomes.
All renal biopsies were examined by the same pathologist
(M.P.S.) and classified in accordance with the recommenda-
tions of the ISKDC [27]. The specimens were also scored
for signs of activity and chronicity [6, 28]. Our modified
scoring system was based on mesangial matrix expansion/
mesangial proliferation (0–3) and percentage of glomeruli
with crescent formation (0–3) as indicators of activity, and
on percentage of global glomerular sclerosis (GGS) and
segmental glomerulosclerosis (SGS) (0–2) and extent of
interstitial fibrosis (0–3) as indicators of chronicity. The
scoring of interstitial fibrosis was doubled, due to its impact
on progressive histological damage [4, 29, 30].
Statistical analysis
Statistica 7.0 (Statsoft Inc., Trulsa USA) was used for all
calculations. All data were expressed as mean (standard
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deviation) or median (minimum–maximum) if not normally
distributed. Comparisons between groups were made with
Student’s t-test or Mann–Whitney U test, and repeated
measurements with Wilcoxon’s matched pairs test. A chi-
square test was used for comparisons of proportions. P<0.05
was considered statistically significant.
Results
There were no differences in any variable [GFR, ERPF, serum
albumin, MAP, Ua/c, urine immunoglobulin G/creatinine
ratio (UIgG/c)] at any time point between IgAN and HSN
patients. Figure 1 illustrates the Ua/c during follow-up. Thus,
we have pooled the results from both disease populations.
Group A (n= 18) treatment with MP and CYC-P
in combination with ACEi/ARB
After three pulses of MP intravenously, the patients’ Ua/c
ratios decreased from a median of 739 (149–3335) mg/
mmol to 293 (77–1647) mg/mmol, P=0.0012 (Table 1).
After the patients had received additional CYC-P, their
Ua/c ratios decreased further to 99 (2–1094) mg/mmol,
P=0.00002 compared with the first visit. This effect was
maintained at 1 year after start of treatment and at the
last visit. Figure 1a shows that the effects of treatment
were similar in IgAN and HSN patients. UIgG/c decreased
from a median of 29 (0.1–69) mg/mmol to 7 (1–48) mg/
mmol, P=0.022, after treatment with MP and CYC-P,
and this response was maintained at 1 year and at the last
visit. Serum albumin increased significantly through the
follow-up (Table 1). GFR increased from a median 77 (4–
120) ml/min per 1.73 m2 to 105 (8–133) ml/min per
1.73 m2 after treatment, P=0.02, and remained normal
during follow-up (Table 1). ERPF (data not shown) was
normal at onset and did not change significantly during
follow-up. MAP was normal at onset and did not change
during the follow-up.
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Fig. 1 a Urine albumin/creatinine ratio in 11 HSN and 7 IgAN
patients in group A during follow-up. MP methylprednisolone, CYC-P
cyclophosphamide. b Urine albumin/creatinine ratio in 13 HSN and
12 IgAN patients in group B during follow-up. Data are presented as
means with 95% confidence intervals
Table 1 Urine albumin/creatinine ratio (Ua/c), serum albumin and GFR at first visit, at 1 year after start of treatment, and at the last visit, in
groups A and B. For Ua/c, serum albumin (S-albumin) and GFR, the P values are calculated for comparison with the first visit in each group,
using the Wilcoxon pairs test. (n.s. not significant)
Parameter First visit One year after treatment Last visit
Ua/c Number mg/mmol Number mg/mmol P vs first visit Number mg/mmol P vs first visit
Group A 18 739 (149–3335) 17 40 (2–587) 0.0004 17 23 (2–406) 0.0003
Group B 25 237 (4–1263) 23 18 (1–397) 0.0005 21 18 (1–1245) 0.0001
S-albumin Number g/l Number g/l P vs first visit N g/l P vs first visit
Group A 18 24 (10–35) 17 35 (27–42) 0.0003 17 39 (31–44) 0.0003
Group B 25 30 (9–45) 21 40 (13–45) 0.001 19 40 (23–47) 0.0003
GFR Number ml/min per
1.73 m2
Number ml/min per
1.73 m2
P vs first visit Number ml/min per
1.73 m2
P vs first visit
Group A 18 77*** (4–120) 17 108 (23–143) 0.023 17 104** (7–133) n.s.
Group B 25 100* (2–147) 22 112 (10–164) n.s. 21 102*** (10–139) n.s.
***P<0.001, **P<0.01, *P<0.05 vs control subject value of 116 (98–140) ml/min per 1.73 m2 body surface area (Mann–Whitney U test)
rine albumin/creatinine ratio (Ua/c), serum albumin and
GFR at first visit, at 1 year after start of treatment, and at the last visit,
in groups A and B. For Ua/c, serum albumi (S- lbumin) and GFR, the
P values are calculated for comparison with the first visit in each
group, using the Wilc xon pairs test (n.s. not signif cant)
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Group B (n= 25) treatment with ACEi/ARB
with or without corticosteroids
Ua/c decreased and serum albumin increased significantly
during follow-up (Table 1). Figure 1b shows that the effects
of treatment on Ua/c were similar in HSN and IgAN
patients. However, patients treated with ACEi/ARB and
corticosteroids had a higher Ua/c at first visit, a median 391
(44–1,263) mg/mmol, than patients treated with ACEi/ARB
alone, a median 44 (4–778) mg/mmol, P=0.012. The
ACEi/ARB- and corticosteroid-treated group showed a
greater fall in Ua/c (a median decrease of 286 mg/mmol,
73% of the first value) than the group not treated with
corticosteroid (a median decrease in Ua/c of 27 mg/mmol,
61% of the first value). GFR was unchanged during
follow-up.
Renal biopsy
ISKDC ≥ grade III was found in 94% of patients in group A
and in 72% in group B. Group A patients had significantly
more crescents, a median 22 (0–67)%, than group B, a
median 0 (0–65)%, P=0.0007, and the mean activity index
was 2.72±0.75 in group A, significantly higher than the
1.64±1.29 in group B, P=0.0027.
In the nine patients that had undergone repeat biopsy,
comparisons between the first and second renal biopsy
showed that the activity index had declined from 3.11±0.8 to
1.55±1.5, P=0.0008. On the other hand, the chronicity index
had increased from 2.11±1.8 to 4.33±2.2, P=0.008, with the
SGS having increased from a median of 11% to 31%, P=
0.049, and the GGS from a median 0% to 20%, P=0.036.
Patients who developed end stage renal disease
The rate of development of ESRD was 14% (four IgAN and
two HSN). Table 2 shows the clinical parameters in the six
patients (four boys) who developed ESRD in comparison
with the 37 who did not. In summary, the ESRD patients
had lower GFR and higher Ua/c and U IgG/c at the first
visit and at the follow-up visits than did the group that did
not have ESRD. All ESRD patients had been over 9 years
old at onset, and all except one patient had severe features
at onset. The renal biopsy results showed ISKDC grade III
in two patients, ISKDC IV in three patients and ISKDC V
in one patient. The six patients who had progressed to
ESRD had higher a percentage of SGS (median 33) in the
first biopsy than did the patients without ESRD (median 8),
P=0.014.
Outcome
Of the 43 patients, 26 (60%) had a good outcome (9/18 in
group A, 17/25 in group B) and 17 (40%) had a poor
outcome (9/18 in group A, 8/25 in group B). A total of 18
patients (42%) had a complete recovery (7/18 in group A,
11/25 in group B) and were healthy at the last visit. Age at
onset did not predict outcome.
The clinical picture at onset progressed in 14 patients to
the time of the first renal biopsy. All five patients with a
primary presentation of hematuria had developed protein-
uria at the time of renal biopsy, and seven patients with
mild proteinuria at onset had progressed to nephritic,
nephrotic or nephritic–nephrotic syndrome at renal biopsy,
and an additional two patients from nephritic or nephrotic
syndrome to a mixed form. In view of this progressive
worsening of clinical features between onset and the time of
renal biopsy, we have chosen to present the outcome in
relation to clinical features at the time of renal biopsy
(Table 3). Sixteen of 29 patients (55%) with severe clinical
features had a good outcome compared with 10/14 (71%)
of the patients with mild clinical features [P not significant
(n.s.)].
Table 3 also gives the outcome in relation to biopsy
findings. The duration of the disease before the biopsy did
not differ between the group with good (1.4±2.4 years)
and with poor (0.4±0.75 years, P=0.058) outcome. Of
all the renal biopsies, 81% showed advanced findings
Table 2 Patients who had
progressed to ESRD vs those
who had not. GFR and
proteinuria at the first visit, at
1 year after start of treatment,
and at the last visit.
Parameter With ESRD (n=6) Without ESRD (n=37) P
median (range) median (range)
GFR, ml/min per 1.73 m2 42 (2–73) 98 (4–147) 0.004
Ua/c, mg/mmol 1,255 (568–1,754) 388 (4–3,335) 0.006
UIgG/c, mg/mmol 47 (13–83) 6 (0–69) 0.02
At 1 year after treatment n=5 n=35
GFR, ml/min per 1.73 m2 32 (10–68) 114 (54–164) 0.0007
Ua/c, mg/mmol 316 (4–587) 18 (1–397) 0.02
UIgG/c, mg/mmol 11 (0–32) 2 (0–19) 0.03
At the last visit n=5 n=33
GFR, ml/min per 1.73 m2 11 (7–20) 106 (60–139) 0.0004
Ua/c, mg/mmol 388 (62–1,245) 14 (0–247) 0.002
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(ISKDC ≥ III). Nineteen of 35 (54%) of these had a good
outcome in comparison with 7/8 (87%) with milder renal
biopsy findings (ISKDC < III), P=n.s.. Thus, neither
clinical features at renal biopsy nor renal biopsy grade
significantly predicted outcome. However, patients with
poor outcome had significantly lower GFR at the first visit
and lower GFR, higher MAP and Ua/c, and lower serum
albumin (S-albumin) 1 year after treatment than did those
with a good outcome. Comparing renal biopsy findings
between the groups we found a higher percentage of SGS
and a higher amount of interstitial fibrosis and interstitial
inflammation in the group of patients with poor outcome
(Table 4).
There was no significant difference in outcome between
the HSN group and the IgAN group. Fifteen of 24 (63%)
patients in the HSN group and 11/19 (58%) in the IgAN
group had a good outcome. Neither the clinical features nor
the ISKDC grading could predict outcome in these two
groups.
Discussion
Severe HSN and IgAN in childhood are not common, and
there is no consensus on treatment strategies. The aim of this
study was to describe our experience at a single center of the
Table 3 Outcome in relation
to clinical features at the
time of renal biopsy and to
ISKDC grading at the
first renal biopsy
χ2 P=n.s.
Clinical features at biopsy Outcome groups
Number a b c d
Group A 18 7 2 5 4
Mild 1 0 0 1 0
Severe 17 7 2 4 4
Group B 25 11 6 6 2
Mild 13 6 4 3 0
Severe 12 5 2 3 2
Good outcome (a+b) 26 Poor outcome c+d) 17
Mild features at biopsy 10 4
Severe features at biopsy 16 13
Biopsy grade (ISKDC)
Outcome groups
Group A 18 7 2 5 4
ISKDC < III 1 1 0 0 0
ISKDC ≥ III 17 6 2 5 4
Group B 25 11 6 6 2
ISKDC < III 7 5 1 1 0
ISKDC ≥ III 18 6 5 5 2
Good outcome (a+b) 26 Poor outcome (c+d) 17
ISKDC < III 7 1
ISKDC ≥ III 19 16
Table 4 Clinical features at
first visit, at 1 year after
start of treatment and first renal
biopsy findings in relation
to outcome
Clinical features Good outcome (n=26) Poor outcome (n=17) P
Median (range) Median (range)
At first visit
GFR, ml/min per 1.73 m2 115 (4–147) 62 (2–100) 0.00026
One year after treatment
GFR, ml/min per 1.73 m2 119 (80–164) 68 (10–127) 0.00002
MAP, mmHg 78 (58–96) 86 (68–105) 0.0085
Ua/c, mg/mmol 13 (1–397) 116 (2–587) 0.0048
Serum albumin, g/l 40 (25–45) 33 (13–41) 0.004
Renal biopsy findings
SGS, % 0 (0–33) 22 (0–75) 0.0002
Interstitial fibrosis 0 (0–1) 1 (0–2) 0.002
Interstitial inflammation 0 (0–2) 1 (0–2) 0.0125
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effects of treatment in 43 cases of severe HSN and IgAN in a
10-year follow-up study. The study was retrospective and,
therefore, has its limitations. The patients’ data were
retrospectively analyzed and grouped according to the
treatment given. The study groups both differed and over-
lapped in the severity of clinical features and renal biopsy
morphology, and therefore no comparisons to prove efficacy
of the different treatments can be made. The treatment
tradition has also been changed over time. However, some
important observations can be made. Intravenous treatment
with MP was associated with a decline in Ua/c, and, after
additional oral treatment with corticosteroids and CYC-P in
combination with ACEis and ARBs, GFR increased and
both Ua/c and UIgG/c decreased further. In the group not
treated with CYC-P, the Ua/c was also reduced, while the
GFR remained unchanged through the follow-up.
Although several questions are left unsolved regarding
the indication and timing of the treatment, many inves-
tigators emphasize the importance of early treatment in
severe IgAN and HSN, as the morbidity rate is high among
patients with ISKDC grades ≥ III and nephrotic range
proteinuria [11, 17, 28, 31]. We found a decrease in
proteinuria and an increase in GFR following the cortico-
steroid treatment, and, in group B, 68% of the patients had
a good outcome at the last visit. The decline in proteinuria
and preservation of GFR after treatment with cortico-
steroids in severe IgAN and HSN have been shown by
others [11–13]. The further decline in Ua/c after additional
CYC-P therapy found in our study has also been shown in
small series of high-risk patients [8–10, 15, 16]. On the
other hand, CYC-P as single therapy was not shown to be
more effective than supportive therapy [32]. In our study
50% of the patients treated with corticosteroids and CYC-P
had a good outcome after a median 3.1 years, and no severe
side effects were seen.
In our study neither the clinical features (mild or severe)
nor the ISKDC grade of the biopsy (< III or ≥ III) could
predict outcome, which has also been reported by other
authors [2, 16, 27, 31, 33]. An early biopsy is, however,
informative and of great importance for the further
decision to treat. A high proportion of crescents in the
first renal biopsy indicated treatment but did not predict
poor outcome in our study. Instead, we found that a high
percentage of SGS was more frequent among patients
with poor outcome. Several investigators have reported
that the number of crescents in the biopsy have a strong
relation to outcome [15, 16, 34], while others have
indicated that the predictive role of crescents is more
controversial [1, 3, 35]. In our study, one patient who was
anuric and had 67% of crescents in the first biopsy was
treated as in group A and underwent peritoneal dialysis for
5 days. The patient recovered and 3 months later, he had
normal GFR and blood pressure and only microalbuminuria.
Four years after onset he is still healthy and takes no
medication. In contrast, another patient who had nephrotic
proteinuria, reduced GFR and a high percentage of SGS in
the first biopsy, which were all resistant to intervention, went
to ESRD within 6 months, despite aggressive treatment.
Fourteen percent of the patients progressed to ESRD, which
is in agreement with other reports [15, 32, 33, 36]. Those
patients had a lower GFR, greater proteinuria, and more
severe morphological findings in their first renal biopsy, as
has been reported in other studies [1, 4, 35, 37, 38].
In conclusion, we emphasize the value of an early biopsy
in patients with severe clinical features. Treatment with MP
and CYC-P in combination with ACEi/ARB, and treatment
with corticosteroids in combination with ACEi/ARB, was
efficient in reducing proteinuria and improving GFR in both
HSN and IgAN patients. Although further studies are needed
to determine the role of immunosuppression, our study
shows that 50% of the patients undergoing the combined
treatment had a good outcome at follow-up, despite severe
clinical features and advanced renal biopsy findings.
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Abstract Factors predictive of renal outcome were studied
in 78 children with Henoch–Schönlein nephritis followed
up for as long as 17 (mean 5.2) years. Patients with a good
outcome (74%) were healthy or had microalbuminuria or
mild proteinuria at the final follow-up (FU), and those with
poor outcome (26%) had active renal disease or chronic
kidney disease at stages IV–V. Patients with mild symptoms
at onset (hematuria ± mild proteinuria) had a poor outcome
in 15% of cases versus 41% of those with severe symptoms
(nephritic or nephrotic syndrome or nephritic-nephrotic
picture) (p=0.011). However, among patients with mild
proteinuria at onset, 18% showed a poor prognosis; non-
nephrotic proteinuria with a urine albumin/creatinine ratio
at a cut-off value of >144 mg/mmol at the 1-year FU was
predictive of a poor outcome. Among 59 biopsied patients,
37% of those with advanced histological findings [Interna-
tional Study of Kidney Disease in Children (ISKDC) stages
III–V] had a poor outcome compared to none of those with
mild findings (ISKDC stages I–II) (p=0.0015). Patients
with a poor outcome were older at onset, had more
proteinuria, and lower glomerular filtration rate at the 1-
year FU compared with patients with a good outcome.
Multivariate analysis showed that proteinuria at the 1-year
FU and the ISKDC grading score of the renal biopsy were
the two most discriminant factors of a poor prognosis.
Keywords Glomerular filtration rate . Outcome .
Predictors . Proteinuria . Renal biopsy findings
Introduction
Henoch–Schönlein purpura (HSP) is the most common
vasculitis in childhood, with an estimated annual incidence
of 10–20/100 000 children [1–3]. It is an acute leucocyto-
clastic vasculitis, and although it is generally considered to
be a self-limiting disease in the majority of cases, the long-
term prognosis depends on the severity of renal involve-
ment. Henoch–Schönlein nephritis (HSN) occurs in 35%
(range 20–60%) of patients with HSP [2, 4–7]. In
unselected cohorts of patients with HSP, the estimated risk
of end stage renal disease (ESRD) is around 2% [1, 8]. In
contrast, morbidity is low in patients with HSN who have
hematuria and mild proteinuria at onset, while it is higher
among those with more severe renal disease, as in a
nephritic, nephrotic or a nephritic/nephrotic onset [9–12].
The risk of patients selected for treatment at tertiary centres
developing ESRD is 5–20% [12–16]. Given the urgent
need to reduce disease progression to ESRD in these
patients, we retrospectively studied 103 children with HSN
with the aim of identifying prognostic factors of a poor
outcome.
Materials and methods
Our clinic is one of two referral centers for pediatric renal
diseases in Sweden that treats patients with acute and chronic
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renal diseases, including those requiring a renal biopsy. A total
of 103 patients (51 boys), mainly referral patients, with a
median age 8.9 years (range 2.0–17.1 years) at onset were
included in the study which covered the period between
January 1995 and March 2008. All patients were investigated
at our clinic within 1.5 years (median 0.34 years) from disease
onset. Of the 103 patients, 38 were lost to late (>1.5 years)
follow-up (FU). An additional 13 patients referred to our
clinic later than 1.5 years after disease onset and one patient
who reached terminal renal failure within 0.7 years from onset
was also included in the late-FU group. Therefore, we had a
late study group of 78 patients who were investigated within
5.2±3.2 years from onset; 44 of these patients were also
studied 1 year from onset.
The patients were subdivided into five classes according
to the renal manifestations at onset [4]: (1) micro- or
macroscopic hematuria; (2) persistent mild proteinuria
[<1 g/L or urine albumin/urine creatinine ratio (Ua/c) <
200 mg/mmol] ± hematuria; (3) nephritic syndrome, i.e.
moderate proteinuria (Ua/c ≥ 200–400 mg/mmol), hematu-
ria, raised serum creatinine and/or hypertension [17]; (4)
nephrotic syndrome: urinary albumin excretion >40 mg/h/
m2 or Ua/c > 400 mg/mmol, serum albumin <25 g/L and/or
oedema; (5) mixed nephritic/nephrotic syndrome at onset.
Classes 1 and 2 were defined as mild clinical features and
classes 3–5 as severe.
The glomerular filtration rate (GFR) was determined at
admittance and during the FU by renal clearance of inulin
during water diuresis [18] or by plasma clearance of
iohexol using the slope curve. A group of 50 healthy
children aged 10.1±4.6 years served as controls; their mean
GFR was 116±11 ml/min/ 1.73 m2. Blood pressure (BP)
was measured with an oscillometric device (Dinamap,
Newport, RI). Systolic (SBP), diastolic (DBP) and mean
arterial blood pressure (MAP) were measured and then
adjusted for gender, age and height. Hypertension was
defined according to recommendations from the Working
Group of National High Blood Pressure Educational
Program [17]. Of the 103 patients, 70 had a renal biopsy
performed within 1.4±0.7 years from onset, and 59/78
patients in the late study group were biopsied. The biopsies
were all examined by the same pathologist (MPS) and
analysed in accordance with the recommendations of the
International Study of Kidney Disease in Children (ISKDC)
[19]. Thirty of the 78 patients in the late-FU group (38%)
were treated: 13 with methylprednisolone pulses followed
by oral prednisolone and 14 with additional cyclophospha-
mide (CYC-P); all 30 received angiotensin converting
enzyme inhibitors (ACEi) and/or angiotensin II receptor
blockers (ARB). Our treatment indications have been
discussed in a previous article [20]. The most severe cases
were treated. Compared to the untreated group, the treated
patients had higher Ua/c (p=0.0006) and urine immuno-
globulin G/c (UIgG/c; p = 0.018) ratios and lower GFR
(p=0.029) at onset and a higher ISKDC grading score
(p=0.002) in the biopsy. The mean FU time in the treated
group was 4.8±3.1 years and in the non-treated group 5.4±
3.3 years. Twenty-one of the 29 patients with crescents
were treated: nine with methylprednisolone and oral
steroids and 12 with additional CYC-P.
The patients were categorized into four groups based on
outcome: A, no or minor urinary abnormalities, i.e. healthy
patients and those with microalbuminuria (Ua/c 2.5–25 mg/
mmol) with or without hematuria; B, persistent mild
proteinuria (Ua/c > 25–200 mg/mmol) and normal GFR;
C, active renal disease, i.e. Ua/c > 200 mg/mmol and/or
GFR 31–93 ml/min/1.73 m2 and/or hypertension; D CKD
stages IV–V, GFR≤30 ml/min/1.73 m2 or ESRD requiring
dialysis and/or renal transplantation. Categories A and B
were defined as good outcome and categories C and D as
poor.
The study was approved by the Ethics Committee at the
Karolinska Institutet.
Statistical analysis
Statistica 7.0 (Statsoft, Tulsa, OK) was used for all
calculations. Variables were expressed in terms of the mean
and standard deviation (SD) or, if the data were skewed, as
the median and minimum–maximum. The Ua/c was log
transformed to obtain normal distributed data. Comparisons
between groups were made with Student’s t test for
normally distributed data and with the Mann–Whitney U
test for data with skewed distribution. The chi-square test
was used for comparisons of proportions, i.e. categorical
variables. Linear regression was used to explore the linear
relation between continuous variables and the Spearman
correlation between ordinal variables or combination
ordinal and continuous variables. Logistic regression
(univariate model) was used to explore the discriminators
of poor outcome compared to good outcome. The logistic
regression model estimates the cut-off level where the odds
for a poor outcome exceed 50%. The predictive value of the
model against the observed data was evaluated as percent-
age agreement.
The odds ratios (OR) and their corresponding 95%
confidence intervals (CIs) were calculated. A multivariable
model was constructed including a combination of the
identified predictors. A p value <0.05 was considered to be
statistically significant.
Results
The clinical picture at onset in the 103 patients showed that
12% patients had isolated hematuria, 40% had mild
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proteinuria ± hematuria, 18% had acute nephritic syndrome,
14% had nephrotic syndrome and 16% had a mixed
nephritic–nephrotic picture. Thus, 48% of the patients had
severe clinical features at onset. There were no significant
sex or age differences between the clinical groups at onset.
Mean GFR at the first investigation (GFR:first) was
100±29 ml/min/1.73 m2, which was significantly lower
than that of controls (p=0.0002). One patient was anuric at
onset, and 35% had a GFR:first below −2SD of that of the
controls. The GFR:first correlated inversely with age at
onset, log Ua/c and UIgG/c at the first investigation, log
Ua/c at the 1-year FU (log Ua/c 1y), percentage crescents
(CRE%), degree of mesangial proliferation (MP) and
interstitial inflammation (II) and the ISKDC grading score
(Table 1).
Mean GFR at the last investigation (GFR:last) was 105 ±
27 ml/min/1.73 m2, which was significantly lower than that
of controls (p=0.004). Seventeen patients (22%) had a
GFR below −2SD of that of controls, and 26 patients
reduced their GFR between the first and last investigation
(∆GFR) −3.4 (range −31 to −0.22) ml/min/1.73 m2 per
year. Two patients reached ESRD after 0.7 and 5 years,
respectively, and one had a GFR of 20 ml/min/1.73 m2 at
5.2 years after onset. No deaths occurred.
The GFR:last correlated inversely with age at onset, log
Ua/c and log UIgG/c and systolic hypertension at first
investigation, log Ua/c 1y, percentage segmental sclerosis
(SGS), degree of MP, II, interstitial fibrosis (IF) and the
ISKDC grading score (Table 1). The GFR:last correlated
directly with GFR:first (R=0.406, p=0.008) and with GFR
at 1 year (R=0.518, p=0.003).
Prognostic factors and clinical findings
The relationship between clinical symptoms at onset and
outcome is presented in Table 2, which shows that 58/78
(74%) of the patients had a good outcome (A + B) and that
61% of the patients were healthy or had microalbuminuria
(A) at the last follow-up. In the group with mild symptoms
at onset, 33/46 (72%) achieved a complete recovery,
compared to 15/32 (47%) of those with severe symptoms
at onset (p=0.026). Of the 22 patients with nephrotic or
nephritic-nephrotic picture, 15 (68%) had a good outcome,
with 13 of the 22 (59%) achieving complete recovery.
There was no significant difference in outcome between
patients with nephrotic versus non-nephrotic proteinuria at
onset.
Of the 78 patients, 20 (26%) had a poor outcome (C +
D) at the last investigation. Only 1/12 (8%) patients with
hematuria at onset had a poor long-term outcome, but the
corresponding figure for patients with mild proteinuria was
6/34 (18%, p=nonsignificant). Thirteen of the 32 patients
(41%) with severe symptoms at onset had a poor outcome
(C + D) compared to 7/46 (15%) of those with mild
Table 1 Correlations between clinical features, biopsy findings and renal function at the first and last investigation
Clincal/biopsy findings GFR:first GFR:last
n r p Adjusted r2 n r p Adjusted r2
Clinical featuresa
Age at onset 103 −0.213 0.031 0.045 78 −0.373 0.0008 0.139
Log Ua/c first investigation 100 −0.420 0.00001 0.176 64 −0.295 0.018 0.087
Log UIgG/c first investigation 81 −0.456 0.00002 0.209 52 −0.299 0.031 0.090
Systolic hypertension 30 −0.316 0.089 0.099 22 −0.846 0.000001 0.715
Log Ua/c 1-year FU 62 −0.432 0.0005 0.186 44 −0.495 0.0006 0.245
Biopsy findings
CRE%a 70 −0.334 0.005 0.012 59 −0.231 0.079 0.053
SGS%a 70 −0.200 0.097 0.004 59 −0.271 0.038 0.073
MPb 70 −0.429 0.0002 59 −0.348 0.007
IIb 70 −0.302 0.01 59 −0.262 0.045
IFb 70 −0.109 0.368 59 −0.346 0.007
ISKDC gradingb 70 −0.308 0.009 59 −0.334 0.01
r, Regression coefficient; log Ua/c, log urine albumin/urine creatinine ratio; log UIgG/c, log urine immunoglobulin G/urine creatinine ratio; GFR,
glomerular filtration rate; CRE%, percentage of glomeruli with crescents; SGS%, percentage with segmental glomerulosclerosis; MP, mesangial
proliferation; II, interstitial inflammation; IF, interstitial fibrosis; ISKDC, International Study of Kidney Disease in Children; FU, follow-up
a Linear regression was used between continuous variables i.e. for all clinical variables and CRE% and SGS%
b Spearman´s correlation was used between ordinal variables i.e. MP, II, IF and ISKDC grading
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symptoms (p=0.011). Three of the 78 patients (4%) had
CKD IV–V (outcome D) at the last visit. Comparisons
between mild and severe symptoms at onset in relation to
outcome remained significant even if the FU was >3 years
(57 patients) (p=0.03), significance was lost when the FU
was >5 years (31 patients).
There was no statistical difference in outcome between
patients who had normal GFR at onset or 1 year and those
with impaired GFR at these same time points. Figure 1
shows GFR:last in relation to FU in patients with different
levels of proteinuria at the first investigation. Patients with
micro- or no albuminuria had—with few exceptions (three
patients)—normal levels of GFR:last, whereas GFR:last
was impaired in 14 patients with proteinuria levels above
microalbuminuria.
At the 1-year FU, patients with a poor outcome were
older at disease onset (10.9±3.7 vs. 8.9±3.4 years, p=
0.036) and had a higher Ua/c 1 y [mean 179 (range 0–568)
vs. 10 (0–160) mg/mmol, p=0.002] and lower GFR (91±33
vs. 107±17 ml/min/1.73 m2, p=0.047) than patients with a
good outcome. There was no difference in outcome
between patients who were normotensive and those who
were hypertensive (n=22) at the first investigation.
Prognostic factors and biopsy findings
Signs of acute lesions, such as CRE, were detected in 49%
of the biopsies, mesangial matrix expansion (MM) in 58%
and MP in 98%; in comparison, chronic lesions, such as
global glomerulosclerosis (GGS), were detected in 32% of
the biopsies, SGS in 44%, II in 41% and IF in 44%. IF was
mild to moderate (grade 1–2), and there were no cases of
advanced (grade 3) IF findings. Table 3 presents the
outcome in relation to biopsy findings. The time from
onset to biopsy did not differ between the outcome groups.
ISKDC III was the most common biopsy finding,
diagnosed in 42% of the cases. Advanced findings (III–V)
were found in 64% of the patients, of whom 37% had a
poor outcome; in comparison, none of those with mild
histology (I–II) had a poor outcome (p=0.0015). Compar-
ison between advanced and mild histological findings in
relation to outcome remained significant even if the FU was
≥3 or ≥5 years (p=0.002 for both groups). The outcome in
relation to individual lesions showed that patients with SGS
Table 2 Outcome in relation clinical features at onset
Symptoms Categories of patients based on clinical features at onset (n = 78 patients)a
A B C D
Mild symptoms:
Hematuria 11 0 1 0
Mild proteinuria ± hematuria 22 6 5 1
Severe symptoms:
Acute nephritic syndrome 2 2 6 0
Nephrotic syndrome 5 0 3 0
Nephritic–nephrotic syndrome 8 2 2 2
Total 48 (61%) 10 (13%) 17 (22%) 3 (4%)
Ua/c, Urine albumin/urine creatinine ratio; CKD, chronic kidney disease
Number of patients per category per symptom are given
a A, Patients had no or minor urinary abnormalities, i.e. healthy patients and those with microalbuminuria (Ua/c 2.5–25 mg/mmol) with or without
hematuria; B, patients had persistent mild proteinuria (Ua/c > 25–200 mg/mmol) and normal GFR (≥94 ml/min/1.73 m2 ); C, patients with active
renal disease, i.e. Ua/c > 200 mg/mmol and/or GFR 31–93 ml/min/1.73 m2 and/or hypertension; D, patients at CKD stages IV–V
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Fig. 1 Glomerular filtration rate at last investigation (GFR:last) in
relation to time of follow-up and grade of proteinuria at the first
investigation. Ualb/Ucreat Urine albumin/urine creatinine ratio (mg/
mmol). Ualb/Ucreat <25 Normo- or microalbuminuria, Ualb/Ucreat
25–200 mild albuminuria, Ualb/Ucreat >200–400 moderate albumin-
uria, Ualb/Ucreat >400 nephrotic albuminuria
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had a poorer outcome than those without SGS (p=0.018),
but a comparison of patients with crescents to those without
(p=0.056) or those with GGS to those without (p=0.747)
revealed no difference in outcome. Moreover, patients with
poor outcome had a higher degree of MM (2–3 vs. 0–1, p=
0.005), MP (2–3 vs. 0–1, p=0.002), II (1–2 vs. 0, p=0.007)
and IF (1–2 vs. 0, p=0.018) than did those with a good
outcome. Log Ua/c at the first investigation correlated to
ISKDC grading score (r=0.399, p=0.0008), MM (r=0.363,
p=0.0024) and MP (r=0.452, p=0.0001), whereas the log
Ua/c 1y correlated to ISKDC grading score (r=0.504, p=
0.0003), MP (r=0.512, p=0.0002) and II (r=0.483, p=
0.0006).
Of the 30 treated patients, 12 (30%) had a poor outcome
compared to 8/48 (16%) of the untreated patients (p=0.02),
and no significant difference in outcome was found
between the treated and untreated patients with crescents.
Neither was there any significant difference in ∆GFR
between treated and untreated patients.
Univariate and multivariate analysis of risk factors
The logistic regression univariate analysis identified clinical
and morphological predictors of poor outcome (Table 4). Of
the clinical variables, age at onset (p=0.044), SBP, clinical
features at onset (p=0.017), SBP, serum albumin and log
Ua/c 1y (p=0.010) discriminated between a good and poor
prognosis. Hypertension at the first investigation or at the
1-year FU was not predictive. Among the morphological
lesions, high amounts of MM, MP, II and IF were each
identified as individual predictors and the ISKDC grading
score was highly predictive (p=0.002).
Based on the results of the univariate analysis, we
included four variables into the multivariate model: age at
onset, clinical features at onset, log Ua/c 1y and ISKDC
grading score. Adding FU-time as a co-dependent variable
to each of these four variables did not change their
predictive significance. According to the multivariate
analysis, the combination of ISKDC grading score and
log Ua/c 1y gave the highest agreement to the model
(92%). However, these two variables were strongly inter-
related, and only the log Ua/c 1y maintained its significance
(OR 2.52, 95% CI 1.20–5.27, p=0.015). The observed cut-
off level for poor outcome in terms of Ua/c 1y was
estimated to be e4.98. Thus, a level of Ua/c at 1 year above
or below 144 mg/mmol discriminated between poor and
good outcome with a sensitivity of 95% and specificity of
40%, (positive predictive value 82%, negative predictive
value 73%).
Discussion
In our study, 41% of patients with severe symptoms at
onset had a poor outcome, which is a significantly larger
proportion than that among those with mild symptoms
(15%). Several authors have discussed the relation between
clinical symptoms at onset and prognosis [4, 9–16, 21].
Patients with isolated hematuria showed a good prognosis,
both in our study and in other studies reported in a review
article [11], but there are exceptions [12]. Mir et al. reported
a good outcome in 91% of patients with mild proteinuria at
onset [21]. In contrast, we found as many as 18% of
patients with mild proteinuria at onset with a poor outcome,
which is in the same range as that reported by others [10,
22]. In a previous article [23], we reported that advanced
morphology can be found in biopsies from patients with
mild proteinuria. Thus, the level of proteinuria at onset does
not seem to be a reliable predictor. However, proteinuria
during FU was of high prognostic significance in our study,
which is in agreement with the results reported elsewhere
[9, 24]. We found that cut-off Ua/c levels at 1 year as low
as 144 mg/mmol were highly predictive of a poor outcome.
Special attention was also given to patients with nephrotic
syndrome or with a nephritic–nephrotic picture at onset, as
such patients are known to be at risk of a poor outcome [10,
14, 19, 21, 25, 26]. Nevertheless, we found a high recovery
rate among these patients, which is in accordance with the
Histology findings Categories of patients based on clinical features at onset (n = 59 biopsies)a
A B C D
Mild histology findings
ISKDC I 4 2 0 0
ISKDC II 13 2 0 0
Advanced histology findings
ISKDC III 15 4 5 1
ISKDC IV 4 0 5 1
ISKDC V 0 1 1 1
Total 36 (61%) 9 (15%) 11 (19%) 3 (5%)
Table 3 Outcome in relation to
biopsy findings
a For definition of clinical clas-
sification of patients at onset,
see text and footnotes to Table 2
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reports of others [15, 27]. We did not find any difference in
outcome between patients with nephrotic or non-nephrotic
proteinuria at onset. We also found a correlation between
GFR:first and GFR:last, which is in agreement with the
findings of Schärer et al. [14] who reported an initial renal
insufficiency as a predictor of poor outcome. Others did not
find low GFR at onset to be a predictor [9, 24], and indeed
neither chi-square nor logistic regression analysis could
confirm our findings of GFR:first being a predictor of poor
prognosis.
We also did not find any difference between sexes in
relation to outcome, which is in contrast to the findings
published by a number of other authors [9, 10], who found
that women ran a markedly greater risk of a poor long-term
outcome.
In our study, age at onset was a predictor of poor
prognosis in univariate analysis but not in multivariate
analysis. Older children tend to have more severe disease at
presentation [25], but age at onset has not been shown to be
a predictor of poor outcome [10, 15, 19]. Age-adjusted SBP
at the first investigation and at the 1-year FU were
identified as predictors of a poor prognosis in the univariate
analysis, but hypertension was not. Consequently, our
findings are in accordance with those of Coppo et al. [9].
We found that the histology grading score was strongly
predictive of outcome.
Several authors have discussed the distinction between
acute and chronic lesions and the predictive importance
thereof. A number of these have stated that glomerular
crescents carry a prognostic significance [4, 13, 14, 19, 24,
28, 29]. However, in agreement with others [9, 30, 31], we
found no such significance. Instead, the amount of
segmental sclerosis correlated inversely to GFR at the last
visit (Table 1), and patients with SGS had a poorer
prognosis than those without this finding. In our study,
the univariate analysis identified both acute lesions (MM,
MP) and chronic lesions (II, IF) as predictors of renal
outcome. In adult HSN patients, the detection of SGS and
the degree of II and IF are predictive of renal outcome [30,
32]. However, advanced IF is a rare finding in pediatric
biopsies, and the outcome is therefore more difficult to
validate.
In an earlier study [20] we demonstrated that treatment
with steroids and CYC-P in combination with ACEi/ARB
is effective in reducing proteinuria and improving GFR in
severe cases of HSN and IgA nephritis. In this study, we
found that a high proportion of treated patients had a poor
outcome, mainly due to the fact that treatment was given to
Clinical variables n OR (unit) 95% CI p % agr
At the first investigation
Age at onset 78 1.17 1.00-1.37 0.044 73
Sex (male vs female) 78 1.5 0.53-4.25 0.436
SBP, mmHg 64 1.05 1.00-1.10 0.038 80
Hypertension (yes vs no) 64 2.29 0.73-7.14 0.152
Log Ua/c, mg/mmol 64 1.20 0.95-1.52 0.131
Log UIgG/c, mg/mmol 52 1.39 0.92-2.11 0.114
GFR, ml/min/1.73m2 65 0.99 0.97–1.00 0.109 74
Clinical features at onset (severe vs mild) 78 3.81 1.29–11.31 0.017
At 1-year follow-up
SBP, mmHg 44 1.06 1.00–1.13 0.038 64
Hypertension (yes vs no) 44 2.27 0.46–11.29 0.307
S-albumin, g/L 38 0.89 0.79–0.99 0.047 68
Log Ua/c, mg/mmol 44 1.69 1.14–2.48 0.010 84
Log UIgG/c, mg/mmol 30 1.85 0.84–4.06 0.120 73
GFR, ml/min/1.73m2 44 0.97 0.94–1.00 0.077 75
Morphological variables (n=59)
GGS% 1.06 0.98–1.00 0.120 76
SGS% 1.03 0.99–1.0 0.080 78
CRE% 1.03 0.99–1.06 0.089 76
IF 1-2 vs 0 4.53 1.19–17.28 0.027
II 1-2 vs 0 5.54 1.44–21.33 0.014
MM 2-3 vs 0-1 6.64 1.57–28.21 0.011
MP 2-3 vs 0-1 7.20 1.88–27.59 0.005 76
ISKDC grading score 5.1 1.87–13.88 0.002 81
Table 4 Logistic regression
(univariate analysis) of factors
that discriminate between poor
and good outcome at the last
visit
SBP, Systolic blood pressure
(age-adjusted); GGS%, per-
centage global glomerulosclero-
sis; MM, mesangial matrix
expansion; OR, odds ratio; CI,
confidence interval, % agr, per-
centage agreement between ob-
served and expected value
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the majority of the severe cases. We did not find crescents
to be a factor of poor prognosis, but 21/29 of the patients
with crescents were treated, which may have improved the
course of the disease. However, treatment was not given
according to any protocol and, consequently, no conclu-
sions on efficacy can be made.
Our study has a number of limitations. Advanced histo-
logical findings were found in 64% of the cases, which
indicates that our cohort was not a random selection of
patients; as such, this over- representation of advanced disease
might have overestimated the poor prognosis. However, the
proportion of severe cases is in the same range as in other
reports of the same size [9, 28]. Secondly, the 38 patients who
were lost for FU could possibly have had a high recovery
rate. However, their clinical features at onset did not differ
from those in the late-FU group, and none of the patients are
in the Swedish Renal Registry. Thirdly, the 13 patients who
were included after >1.5 years of disease duration are likely
to have had a late recurrence or a severe form and, therefore,
may have increased the proportion of patients with poor
outcome in our study. In comparison to rates reported
elsewhere [10, 12–16], our rate of CKD stage IV–V/ ESRD
is still low (4%), which can be explained by a shorter FU.
We conclude that 26% of the patients had a poor outcome
after a mean of 5.2 years. Both severe features at onset and
advanced biopsy findings were associated with poor out-
come. Multivariate analysis showed that the ISKDC grading
score and proteinuria at the 1-year follow-up were the best
discriminators of a good and poor outcome.
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Abstract
Background. There has been a lack of international con-
sensus on the classification and the predictive value of
the histopathology findings in IgA nephropathy (IgAN).
Recently, the International IgA Nephropathy Network
has developed the Oxford classification in which four
histological variables with the most prognostic impor-
tance are identified (MEST score). Our objective was to
validate these findings and to assess their predictive
power in our cohort and to compare them to identified
clinical predictors.
Methods. Ninety-nine children with a follow-up time >5
years were included and investigated with clearances of
inulin or iohexol for glomerular filtration rate (GFR),
proteinuria and blood pressure at biopsy and during fol-
low-up. Biopsies (90/99) were re-evaluated and scored
according to the Oxford classification.
Results. Eighteen patients progressed to a poor out-
come [end-stage renal disease (ESRD) or GFR reduc-
tion >50%]. In the univariate analysis, we found that
mesangial hypercellullarity score >0.5, presence of en-
docapillary hypercellularity or tubular atrophy/intersti-
tial fibrosis of >25% were each associated with a poor
outcome, and also presence of cellular or fibrocellular
crescents and of global glomerulosclerosis, but seg-
mental glomerulosclerosis did not reach statistical sig-
nificance. The clinical predictors of a poor outcome
were a low GFR, a high mean arterial blood pressure
and a high amount of albuminuria (log Ualb/c) at time
of biopsy and low GFR and a high log Ualb/c during
follow-up.
Conclusion. We found that three of the four histology
lesions identified in the Oxford classification, as well as
presence of crescents, were valid in predicting a poor
outcome in our cohort of patients.
Keywords: glomerular filtration rate; IgA nephropathy; Oxford
classification; predictors; proteinuria
Introduction
The natural history of IgA nephropathy (IgAN) shows wide
variability in the clinical setting. Long-term studies of
paediatric IgAN report different progression rates, with a
10-year renal survival of 87–93% and a 20-year renal sur-
vival of 73–89% [1–3]. Several clinical predictors of poor
outcome have been discussed, such as age at diagnosis [4],
severe proteinuria, hypertension and impaired renal func-
tion at presentation [2, 5]. Biopsies show a wide range of
different stages of pathology from nearly normal histology,
apart from deposits of IgA in the glomeruli, to severe path-
ology findings with crescentic or sclerotic/necrotic lesions.
There has been a lack of international consensus in the
validation of previous histopathological classifications [6,
7]. In the new Oxford classification (Oxford MEST score),
the International IgA Nephropathy Network has identified
four histopathological lesions of independent prognostic
importance; mesangial (M) and endocapillary (E) hyper-
cellularity, segmental glomerulosclerosis (S), tubular atro-
phy and interstitial fibrosis (T). The results were analysed
using a systematic approach in order to develop a reprodu-
cible classification which could predict clinical outcome [8,
9]. The Oxford classification score has been shown to be
valid also in paediatric IgAN [10]. Our aim was to assess
the predictability of these findings and clinical variables
among our IgAN patients to improve the prognostic
evaluation.
Materials and methods
Our clinic is one of two referral centres for children with kidney diseases in
Sweden. We studied retrospectively and prospectively 99 consecutive
children and adolescents (58 boys) with a follow-up period of >5 years
up to 36 (mean 13 � 8 years, n ¼ 92) or had reached end-stage renal
disease (ESRD) earlier than after 5 years (n¼ 7). Their mean age was 12�
3.6 years at the first investigation. Two patients died due to non-renal
causes. Forty-seven patients (47%), 29 boys, were followed for >10 years
and 19 patients (19%), 9 boys, for >20 years. The patients were inves-
tigated with clearances of inulin during water diuresis or plasma clearance
of iohexol to determine glomerular filtration rate (GFR) [11] at time of
biopsy and at 1, 3 and 5 years of follow-up and at the last visit. Fifty-nine
� The Author 2011. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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healthy children aged 11.7 � 3.6 years served as controls for GFR. Clinical
baseline characteristics included weight, height, serum creatinine, proteinu-
ria and blood pressure measurements adjusted for gender, age and height.
Systolic and diastolic hypertension was defined as above the 95th percentile
[12]. Proteinuria was measured as the ratio of urine albumin/creatinine
(Ualb/c), defined as normoalbuminuric or microalbuminuric if Ualb/c was
<25 mg/mmol, mild if the ratio was 25–200 mg/mmol, moderate if�200 to
<400 mg/mmol and nephrotic if �400 mg/mmol.
A renal biopsy was performed in all 99 children during 1974–2007.
One-third of the cohort (31/99) was biopsied after the year 2000. Three of
the late biopsied patients deteriorated to ESRD within half a year and they
were included in the study. Ninety specimens were available for review.
The biopsies were performed at a median of 1.6 [interquartile (IQ) range
0.5–4.2] years of disease duration and were examined by one pathologist
(M.P.S.), who was blinded to patient outcome at the time of scoring. The
biopsies were analysed based on 3 l Periodic acid Schiff-stained sections.
There was a median of 16 (IQ range 10–23) glomeruli in each biopsy and
no specimen had <5 glomeruli. The biopsy specimens were classified and
standardized according to the Oxford classification [8], in which the num-
ber of glomeruli was assessed and their mesangial hypercellullarity scored
as �0.5 or >0.5, if more or less than half of the glomeruli showed hyper-
cellullarity defined as >4 mesangial cells/mesangial area, endocapillary
hypercellullarity (absent or present), segmental glomerulosclerosis (absent
or present) and tubular atrophy/interstitial fibrosis (TAIF) (0 ¼ 0–25%, 1
¼ 26–50% and 2¼>50%). The percentage of glomeruli with cellular and
fibrocellular crescents and global glomerulosclerosis (GGS) was calcu-
lated and was classified as absent or present.
Treatment was recorded in three different groups: (i) renin angiotensin
aldosterone system (RAAS) blockade, indicating treatment with ACEis
(angiotensin-converting enzyme inhibitors) or ARBs (angiotensin receptor
blockers) or both, n ¼ 24, (ii) immunosuppression with corticosteroids in
combination with RAAS blockade, n¼ 4 and (iii) immunosuppression with
corticosteroids and cyclophosphamide in combination with RAAS block-
ade, n ¼ 7. Seven patients had received treatment with RAAS blockade
prior to biopsy at a median of 0.13 years from onset and two of these patients
had also received corticosteroids prior to biopsy. Treatment during follow-
up was given on clinical indications and did not follow any protocol.
The primary outcome was defined as poor if GFR:last was reduced
>50% from GFR:bio or if the patient had reached ESRD.
Statistical analysis
Statistica 9.0 (Statsoft Inc., Tulsa, OK) was used for all statistical analyses.
Variables were expressed as the mean and SD for continuous and approx-
imately normally distributed variables and the median and IQ range for
skewed data. The Ualb/c was log-(e)-transformed to obtain approximately
normally distributed data. To test for differences between groups, Student’s
t-test was used for approximately normally distributed data and the Mann–
Whitney U-test for data with a skewed distribution. The chi-square test was
used to test for differences between proportions, i.e. categorical variables.
The Spearman correlation coefficient was used to explore the relationship
between the presence of each histological lesion and treatment and between
one histological and one clinical variable and the Pearson’s correlation
coefficient was used for the relationship between two histological lesions
(Table 4). The Kaplan–Meier curve was used to illustrate univariate differ-
ences between groups of clinical and pathological variables, with respect to
time to poor outcome. Cox proportional hazard regression was used to
estimate the hazard ratio (HR) between groups (levels) within each factor,
by univariate comparisons. Estimates were presented with their correspond-
ing 95% confidence intervals (CIs). Multiple hazard regression was used to
estimate a model including a combination of the independent factors of
interest and was also used to explore which factors were overall the most
important discriminators for time to poor outcome. All tests were two-sided
and a P-value <0.05 was considered as statistically significant.
Results
Clinical predictors
GFR at the time of biopsy (GFR:bio) was 100� 31mL/min/
1.73m2, significantly lower than that of controls, GFR 117�
10 mL/min/1.73m2, (P< 0.001). Seventy-two patients had a
GFR:bio>90mL/min/1.73m2 (chronic kidney disease, CKD
Stage 1) and 25 patients had a reduced GFR:bio: 16 patients
had CKD Stage 2, 4 patients CKD Stage 3, 3 patients CKD
Stage 4 and 2 patients had CKD Stage 5 (ESRD) at the time
of biopsy. In two cases, the GFR was not measured at the
time of biopsy. Thirty patients (30%) were hypertensive at
the time of biopsy. Albuminuria (Ualb/c) was measured in
80 patients at biopsy: 12 had nephrotic levels, 25 had mild
and moderate levels and 43 were normoalbuminuric or
microalbuminuric.
Eighteen patients progressed to poor outcome; 15 (12
boys) developed ESRD after a median of 6 (0.1–14.8) years
from onset and an additional 3 patients reduced their GFR by
50% without progressing to ESRD within the follow-up
period. Four patients, all with risk factors (hypertension
and/or reduced GFR and/or nephrotic proteinuria at biopsy),
had a very rapid deterioration and developed ESRD within 6
months from onset. The annual median rate of renal function
decline (GFR:slope) was �0.8 (IQR �3.1 to 1.2) mL/min/
1.73m2/year if the four patients with very rapid deterioration
were excluded (GFR:slope >50 mL/min/1.73m2/year).
Table 1 shows the differences in clinical variables
between patients with good and poor (n ¼ 18) outcomes.
Patients with a poor outcome had lower GFR, higher mean
arterial blood pressure (MAP) and higher log Ualb/c at the
time of biopsy compared to those with a good outcome.
GFR remained reduced and proteinuria (log Ualb/c) re-
mained increased during follow-up in the poor versus good
outcome group, although the follow-up time was longer in
the good outcome group. The proportion of males with
poor outcome did not differ from that of females 13/58
(22%) versus 5/41 (12%), P ¼ 0.19. The HRs of the pre-
dictors verified in the Cox regression univariate analysis are
shown in Table 2. MAP was identified as a predictor only at
the time of biopsy (HR 1.1, CI 1.05–1.1; P < 0.001) and
not during follow-up.
The 10-year actuarial renal survival in this study was 86%.
Figure 1a–d shows the renal survival with regard to the iden-
tified clinical predictors at biopsy. We found that nephrotic
proteinuria as well as moderate proteinuria, reduced GFR:bio
and hypertension at biopsy were all individual factors of poor
renal survival compared with patients without these risk fac-
tors. The amount of proteinuria at biopsy increased the risk:
Ualb/c >200: HR 23, P < 0.001, n ¼ 17 and Ualb/c >400:
HR 27, P < 0.001, n ¼ 12 compared to the reference Ualb/c
<200 mg/mmol. Proteinuria at follow-up was also shown to
be a powerful predictor; renal survival differed between the
patients with log Ualb/c >200 at 1 year and those with log
Ualb/c <200 (log rank <0.001).
Histopathological predictors
Univariate analysis. Ninety of the 99 biopsies were avail-
able for re-analysis based on the new classification. Table 3
shows the predictive power of the different histological
lesions in the Cox regression analysis. A mesangial hyper-
cellularity score >0.5 (M1), the presence of endocapillary
hypercellularity (E1) and TA/IF of �26% (T1–2) as well as
presence of cellular and fibrocellular crescents (C1) and of
GGS1 were all individual predictors of a poor prognosis in
the univariate analysis in which M1, E1, T1–2 and C1 were
found to have the highest HRs. S1 was not found to be
significantly predictive in the univariate analysis (P ¼ 0.10).
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Figure 2a–f shows the differences in renal survival for
presence and absence of the histological findings and Fig-
ure 3 illustrates the distribution of the frequencies in each
histology lesion. In our cohort, 30% of the patients had
biopsies showing M1, 10% E1, 23% S1, 16% T1–2, 17%
C1 and 29% GGS. The mesangial hypercellularity score was
mean 0.47 � 0.59. Within the group of patients with fibro-
cellular/cellular crescents, the mean percentage was 4.5 �
13.4 and the corresponding figures for segmental glomerulo-
sclerosis% was 3.1 � 7.5 and for GGS% 6.3 � 16.3.
Multivariate analysis. Two multivariate models were
constructed including one single histological lesion in com-
bination with proteinuria at biopsy (Table 3, Model A) and
proteinuria at 1-year follow-up (Model B). We found that
E1 was associated with a significant risk of a poor outcome
in both models, but for all other histological lesions except
S1, the risk of a poor prognosis was significant only in
Model B. When two histological variables were included,
without any clinical variable, the combination of M1/E1
gave the highest risk and when two histological variables
were added in Model A, the combination M1/T1–2 showed
equally high risk as the combination E1/T1–2. In Model B,
the combination of E1/T1–2 showed the highest risk. In the
multivariate model, no combination with S1 added any
predictive information.
Table 1. Comparison of clinical variables at the time of biopsy and during follow-up in patients with good and poor outcomesa
Good outcome Poor outcome
GFR:last reduced >50% of GFR:biob or ESRD
n Mean SD n Mean SD P
Follow-up time, years 81 13.2 7.9 18 8.4 8.8 <0.05
Age at onset 81 9.4 4.0 18 11.1 3.3 0.10
At time of biopsy
GFR 80 107 24.7 17 67 37.9 <0.02
MAP 75 83 9.0 17 96 16.7 <0.001
Log Ualb/c 65 1.1 3.6 15 6.1 1.1 <0.001
At 1 year from onset
GFR 41 114 19.8 9 38 33.6 <0.001
Log Ualb/c 40 1.4 3.0 8 4.5 4.0 0.02
At 3 years from onset
GFR 39 112. 17.6 10 55 40.8 <0.001
MAP 29 83 10.0 8 99 21.1 0.005
Log Ualb/c 36 0.5 3.9 8 5.0 1.6 0.02
At 5 years from onset
GFR 64 112 17.3 8 64 43.4 <0.001
Log Ualb/c 57 1.4 3.1 6 4.9 1.1 0.009
aGFR, mL/min/1.73m2; MAP, mmHg; log Ualb/c ¼ log urine albumin/urine creatinine ratio, mg/mmol.
b GFR:bio ¼ GFR at the time of biopsy.
Table 2. HRs with 95% CIs of clinical variables that discriminate between good and poor outcomes, at time of biopsy and during follow-up (Cox
regression)a
n At biopsy n At 1 year n At 3 years n At 5 years
GFR 97 0.96*** (0.95–0.98) 50 0.95*** (0.94–0.97) 49 0.97*** (0.96–0.98) 72 0.97*** (0.96–0.98)
Log Ualb/c 80 2.31*** (1.66–3.20) 48 1.44** (1.12–1.85) 44 1.43** (1.15–1.79) 63 1.31* (1.00–1.72)
aGFR, mL/min/1.73m2, log Ualb/c ¼ log urine albumin/urine creatinine ratio, mg/mmol.
***P < 0.001, **P < 0.01, *P < 0.05.
Fig. 1. (a–d) Renal survival in relation to clinical variables at biopsy Ualb/c
¼ urine albumin/urine creatinine ratio, mg/mmol, GFR, mL/min/1.73m2.
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Correlations between different histological variables. We
found positive correlations between several histological
lesions shown in Table 4. The strongest correlation of
all histological combinations was found between TA/IF
and GGS (r ¼ 0.83). TA/IF correlated to all other histol-
ogy lesions. We also found strong correlations between
M and E and between C and E. The strongest correlations
among clinical variables with regard to histology were
found between log Ualb/c at biopsy and M1 and
log Ualb/c at biopsy and C1 (r ¼ 0.47, respectively).
GFR:bio correlated inversely with all histological varia-
bles (data not shown).
Table 3. Cox regression analysis of histological variables that discriminate between good and poor outcomesa
Univariate Multivariate
n ¼ 90 HR (95% CI) P n ¼ 74
Model A
HR (95% CI) P n ¼ 44
Model B
HR (95% CI) P
Mesangial hypercellularity score
�0.5 (M0) 62 1 <0.001 49 1 27 1
>0.5 (M1) 28 7.07 (2.25–22.22) 25 0.63 (0.13–3.00) 0.565 17 4.98 (1.43–17.34) 0.012
Endocapillary hypercellularity
Absent (E0) 81 1 66 1 39 1
Present (E1) 9 7.15 (2.21–23.13) <0.001 8 2.52 (0.69–9.16) 0.16 5 6.62 (1.98–22.42) 0.002
Segmental glomerulosclerosis
Absent (S0) 69 1 54 1 31 1
Present (S1) 21 2.38 (0.85–6.70) 0.101 20 0.77 (0.24–2.48) 0.663 13 2.25(0.79–6.38) 0.127
TA/IF
0–25% (T0) 76 1 61 1 37 1
26–50% (T1) 11
5.92 (2.14–16.37)
<0.001 13 2.08 (0.72–6.01) 0.175 7 4.22 (1.48–12.03) 0.007
>50% (T2) 3
Cellular or fibrocellular crescents
Absent (C0) 74 1 58 1 32 1
Present (C1) 16 6.62 (2.14–20.45) <0.001 16 1.42 (0.42–4.83) 0.575 12 6.10 (1.93–19.03) 0.002
GGS
Absent (GGS0) 64 1 50 1 30 1
Present (GGS1) 26 5.23 (1.79–15.3) 0.003 24 2.50 (0.83–7.53) 0.103 14 3.96 (1.33–11.80) 0.014
aThe HRs showing the predictive power of the individual histology lesions in the univariate analysis and in combination with proteinuria (log Ualb/c) at
the time of biopsy (Model A) and at 1-year follow-up (Model B) in the multivariate analysis.
g
Fig. 2. (a–f) Renal survival in relation to histological variables M<0.5 ¼ mesangial hypercellullarity score �0.5 (M0), M>0.5 ¼ mesangial hyper-
cellullarity score >0.5 (M1); E0 ¼ no endocapillary hypercellullarity, E1 ¼ endocapillary hypercellullarity present; S0 ¼ no segmental glomerulo-
sclerosis, S1¼ segmental glomerulosclerosis present; T<25%¼ TA/IF 0–25% (T0), T>25%¼ TA/IF�26% (T1-2); C0¼ no crescents, C1¼ crescents
present; GGS0 ¼ no GGS, GGS1 ¼ GGS present.
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Associations between clinical and histologic
variables. Table 5 shows the association between the his-
tological lesions at the time of biopsy and at the last visit.
All histological lesions (M1, E1, S1, T1–2, C1 and GGS1)
were associated individually with a reduced GFR:bio and a
high log Ualb/c at the time of biopsy. At the last visit, all
histological lesions except S1 were associated with reduced
GFR:last and all except C1 also with a high log Ualb/c last.
The annual GFR reduction (GFR slope) was more prom-
inent among patients with T1–2 findings than among
patients without this lesion (P ¼ 0.016), but no significant
difference in GFR slope was found when comparing
presence (M1, E1, S1, C1, GGS1) with absence (M0, E0,
S0, C0, GGS0) of any other histologic lesion.
Treatment
Thirty-four per cent of the patients had received treatment
from Groups 1–3 (see Materials and methods section). Only
the severe cases were treated. Patients with nephrotic protei-
nuria and/or hypertension at biopsy occurred more frequently
among treated than non-treated patients (P ¼ 0.002 and
P ¼ 0.02, respectively). In the different histology groups,
we found associations to treatment among patients with
T1–2 (r ¼ 0.32, Spearman correlation) and to E1 and C1
(r ¼ 0.22 and r ¼ 0.26, respectively). Immunosuppressive
drugs (IS) were more common among patients with crescents
than among those without (P < 0.001). Treatment with
ACEi/ARB was given more frequently to patients with
TA/IF than to those without this lesion (P ¼ 0.007). The
GFR slope did not differ significantly before (�0.8 � 2.6
mL/min/1.73m2) versus after (�2.0 � 3.4 mL/min/1.73m2)
treatment with ACEi/ARB.
When treatment (IS and ACEi/ARB, respectively) was
added as a clinical variable in the multivariate analysis the
prognostic significance of the histology variables M1, E1,
T1–2, C1 and GGS1 still remained significant.
Discussion
The two main objectives of this study were to identify the
clinical and histopathologic predictors of a poor prognosis
in IgAN and to compare their prognostic power. Many
authors have emphasized the predictive value of the clinical
variables at onset and during follow-up [1, 2], but the con-
troversial issue is whether the histological findings have an
individual impact on the prognostic assessment, independ-
ently of clinical variables [8, 9, 13, 14]. In this study,
GFR:bio, MAP and log Ualb/c at biopsy and GFR and
log Ualb/c at follow-up were found to be clinical predictors
of a poor outcome (Table 2 and Figure 1), with log Ualb/c
at biopsy being the stronger predictor. Our findings that
nephrotic as well as moderate proteinuria and hypertension
at the time of biopsy and proteinuria at follow-up were
predictive factors of a poor outcome (Table 2, Figure 1)
are in agreement with several other authors [1, 2, 13–19].
Fig. 3. Distribution of the level of pathology within each group of histology lesions.
Table 4. Correlations between the different histologic variablesa
E S T C GGS
M 0.54*** 0.27** 0.49*** 0.36*** 0.47***
E n.s. 0.36*** 0.58*** 0.27**
S 0.27** n.s. 0.22*
T 0.24* 0.83***
aM ¼ mesangial hypercellullarity score, E ¼ endocapillary hypercellul-
larity in percentage of glomeruli, S ¼ segmental glomerulosclerosis in
percentage of glomeruli, T ¼ TA/IF Grades 1–2, C ¼ cellular or fibrocel-
lular crescents in percentage of glomeruli, GGS in percentage of glomer-
uli, n.s. ¼ not significant.
*P � 0.05, **P � 0.01, ***P < 0.001.
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We also found a low GFR at biopsy and at follow-up
indicating an unfavourable prognosis in the univariate anal-
ysis but not in the multivariate analysis (Models A and B).
In studies reviewed by Coppo and D’Amico [1, 2], im-
paired GFR at diagnosis was not found to indicate a poor
long-term prognosis among children.
Our results show that each one of the histologic findings
M1, E1, T1–2, C1 and GGS1 was associated with a poor
prognosis, but we did not find S1 to be of statistical prog-
nostic significance (Table 3, Figure 2). However, the low
number of patients might explain why we did not reach
significance with regard to S.
Taking into account the relatively small sample size, en-
docapillary proliferation (E) was shown to be a strong pre-
dictor in this study, although we found a weak association to
treatment. Oxford classification study and other studies have
shown that the amount of E is more frequent, and the amount
of T is less frequent among paediatric patients compared to
adults [8, 10, 20]. In the Oxford classification study, E was
not significantly predictive of a poor prognosis, and the
authors show a strong association to treatment and therefore
E was excluded in their multivariate model.
In our study, special attention was given to patients with
cellular or fibrocellular crescents (C) as they had a high
predictive value (HR 6.6, CI 2.1–20.5) in the univariate
analysis, although it did not maintain its significance in the
multivariate analysis (Model A). This observation is shared
with authors of several other studies reviewed by D’Amico
[2]. Cellular or fibrocellular crescents were not predictive in
the Oxford classification study, due to a low prevalence. In
our study, a higher percentage of patients with C were trea-
ted with immunosuppression and/or ACEi than patients
without this lesion, but treatment did not seem to prevent a
poor outcome, whichmight be due to the interactive effect of
co-existing chronic lesions in the biopsy specimens with
cellular or fibrocellular crescents. We have discussed our
experiences of treatment in the most severe cases of IgAN
and their effect on outcome in a previous paper [21].
TA/IF>26% was found in 16% of the cases and had high
prognostic importance in this study (HR 7.3, CI 2.7–20.2).
In a previous paper from our group, we showed that the
segmental glomerulosclerosis and tubulointerstitial damage
were associated with a low GFR [22]. TA/IF has been shown
to be a strong independent predictor in several studies re-
viewed by D’Amico [2], and in a recent paper [23], the
authors showed that even a small amount of IF increases
the risk of ESRD. As in the Oxford study, we identified a
correlation between GGS and TA/IF (r ¼ 0.83).
When comparing our results with those of the interna-
tional study, certain differences in the design must be ob-
served. In the Oxford classification study, the patients with
initial GFR <30 mL/min/1.73m2 and a urine albumin ex-
cretion <0.5 g/24 h/1.73m2 in children were excluded, and
those with a follow-up of more than a year were included.
When we excluded the first pre-requisite, our results for
renal survival still remained significant for all histological
lesions except crescents (log rank 0.066). Moreover, we did
not exclude patients with urine albumine excretion <0.5 g/
24 h/1.73m2 and we also had different inclusion criteria
regarding disease duration. We selected patients who have
had the disease for >5 years (except for four patients with
very rapid deterioration reaching ESRD within 5 years), in
order to enhance the opportunity of finding independent
prognostic factors of a poor prognosis. In contrast, the
original study included cases after 12 months of disease
duration, to minimize the impact of the most acute and
rapidly progressive cases. In our study of 90 children, the
frequency of patients reaching the end point (GFR reduc-
tion>50% or ESRD) was lower than in the Oxford study of
209 adults and 59 children (18 versus 35%, respectively),
which might be due to the different selections of included
patients.
Table 5. Relations between clinical and histological variables at the time of biopsy and at the last visita
At the time of biopsy At the last visit
GFR Log Ualb/c GFR
Log
Ualb/c
M0 106 6 25 0.9 6 3.7 101 6 30 0.1 6 3.4
M1 84 6 38 4.4 6 2.7 67 6 47 3.0 6 3.1
P 0.002 <0.001 <0.001 <0.001
E0 104 6 28 1.6 6 3.7 94 6 36 0.7 6 3.5
E1 63 6 35 5.1 6 2.4 53 6 54 3.5 6 4.0
P <0.001 0.01 0.003 0.05
S0 106 6 28 1.5 6 3.8 94 6 36 0.5 6 3.6
S1 82 6 33 3.5 6 3.3 78 6 47 2.5 6 3.0
P 0.002 0.04 n.s. 0.03
T0 107 6 22 1.4 6 3.8 97 6 33 0.6 6 3.6
T1–2 65 6 45 4.8 6 1.7 55 6 53 3.2 6 2.8
P <0.001 0.002 <0.001 0.02
C0 105 6 24 1.2 6 3.8 94 6 36 0.6163.57
C1 74 6 44 4.9 6 2.0 71 6 50 2.26 6 3.49
P 0.001 <0.001 0.03 n.s.
GGS0 105 6 27 1.2 6 4.0 99 6 30 0.5 6 3.4
GGS1 88 6 38 3.9 6 2.3 67 6 51 2.3 6 3.7
P 0.02 0.003 <0.001 0.04
aDifferences in GFR and proteinuria at the time of biopsy and at the last visit in the different histology groups. GFR, mL/min/1.73m2, log Ualb/c ¼ log
urine albumin/urine creatinine ratio, mg/mmol, n.s. ¼ not significant. Histologic abbreviations as in Table 3.
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Our Models A and B, including one clinical and one
histological variable, differ from those in the Oxford classi-
fication study in which three clinical and three histological
variables were included. When we replaced log Ualb/c with
GFR bio/GFR 1 year in Models A and B, we did not obtain
any further prognostic information. Due to the low number
of events (n ¼ 18), we could not expand our models.
Our actuarial 10-year renal survival of 86% is in the
lower range of results reported from other centres [1–4]
and poorer than in the Japanese studies (96.4%) [24]. These
results might reflect different indications for renal biopsy in
Europe, in the USA and in Japan [3] and also the different
traditions of treatment over time and between the countries.
Our 10-year renal survival could also be explained by the
fact that our cohort shows a high proportion of advanced
disease, due to referral patients.
In summary, all histological variables except S were
each highly discriminative of a poor prognosis in the uni-
variate analysis. However, in the multivariate analysis, we
found that the discriminative ability was reduced when
histology was combined with proteinuria at biopsy (Table
3, Model A), whereas the ability was more pronounced when
histology was combined with proteinuria at 1-year follow-up
(Model B). The observation might be due to the selection of
patients with a more severe disease in Model B and the
smaller sample size.
The low discriminative power of histological variables in
ourModel A is due to the impact of albuminuria at biopsy, as
only two variables can be included in the multivariate model.
Although a limited number of patients with a poor outcome
in our study could lead to conclusions in the analysis of the
subgroups as underpowered, we still reached some notewor-
thy results. The strengths of this study are the total sample
size and the long follow-up time (mean 13 years with 50% of
the patients with follow-up time of >10 years) and the ac-
curacy of the renal function investigations with GFR being
measured by clearance studies. The limitation is that the
study cohort mainly consists of referral patients which might
overestimate the poor prognosis.
In conclusion, we found that the Oxford classification
score is a valuable tool for prognostic purposes. We also
found in our paediatric population that the presence of
cellular/fibrocellular crescents was of prognostic signifi-
cance as well as albuminuria at biopsy and during fol-
low-up.
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